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ABSTRACT
This dissertation examines the fundamental principles and applicability of the
kinetic exclusion assay (KinExA), developed and marketed by Sapidyne Instruments of
Boise, Idaho, since 1995. Chapter One reviews and consolidates the manufacturer’s
guidance and many early papers that delineate the practical and theoretical aspects of the
technology. In brief, KinExA is a two stage analytical system. In stage one, a number of
solutions are prepared, whereby one of the partners is kept constant (the constant binding
partner, or CBP), while the other (the titrant) is varied, usually in serial dilution. As the
titrant is increased, the free CBP decreases, and is analyzed by a sophisticated and precise
microfluidic fluorometric device (stage two). The resulting signal can be related
mathematically to the affinity (KD) of the two molecules for each other, and to the kinetic
parameters of binding (kon) and dissociation (koff). A comparison of KinExA with other
current technology available for quantification of interactions is provided.
In Chapter Two, I investigate the use of KinExA technology with DNA aptamers.
DNA aptamers are short nucleotide oligomers selected to bind a target ligand with
affinity and specificity rivaling that of antibodies. These remarkable features make them
promising alternatives for analytical and therapeutic applications that traditionally use
antibodies as biorecognition elements. Numerous traditional and emerging analytical
techniques have been proposed and successfully implemented to utilize aptamers for
sensing purposes. In this work, I exploited the analytical capabilities offered by the
KinExA technology to measure the affinity of fluorescent aptamers for their target
vii

molecule thrombin, and quantify the concentration of analyte in solution. Standard
binding curves constructed by using equilibrated mixtures of aptamers titrated with
thrombin were fitted with a 1:1 binding model and provided an effective KD of the
binding in the sub-nanomolar range. However, the experimental results suggest that this
simple model does not satisfactorily describe the binding process; therefore, the
possibility that the aptamer is composed of a mixture of two or more distinct KD
populations is discussed. The same standard curves, together with a four-parameter
logistic equation, were used to determine “unknown” concentrations of thrombin in mock
samples. The ability to identify and characterize complex binding stoichiometry, together
with the determination of target analyte concentrations in the pM–nM range, supports the
adoption of this technology for kinetics, equilibrium, and analytical purposes by
employing aptamers as biorecognition elements.
In Chapter Three, I explore complex capture agents in the KinExA system.
Liposomes made from purified reagents, or from natural cellular membranes, are attached
to the beads used in the KinExA process to capture the analyte. Model molecules
representing lipophilic dyes, antibodies, and bacterial toxins were successfully captured
by the beads for measurement. Residual free ligand captured after pre-equilibration with
membrane components, presented as either liposomes or whole cells, could be quantified,
and kinetic parameters determined. By this process the “bi-molecular” interaction of the
B subunit of cholera toxin for the ganglioside GM1 incorporated into artificial
membranes could be quantified, and shown to be dependent upon the presence of the
ganglioside in the membrane. The diffusion into artificial membranes of the lipophilic
dye DID could be quantified and shown to be dependent upon the amount of lipid

viii

available in the equilibration step. In addition, the bulk affinity of a commercial
polyclonal antibody for the surface antigens of their target red blood cells could be
evaluated. This membrane immobilization process appears to be generally applicable to
any membrane system. Thus, it promises to be valuable for the study of signaling
molecules for which purified soluble target cellular components may result in misleading
information, or for which soluble fragments are unavailable. Likewise, this process
should aid in the search for drugs which mimic or antagonize these signaling ligands.
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CHAPTER ONE: THE KINETIC EXCLUSION ASSAY
Since the discovery of the first enzyme, diastase, in a cell-free solution of malted
barley in 18331, there has been a steady accumulation of detail in the fascinating
functions of individual molecules in biology. The discovery of allosteric control of
enzymatic activity by, among others, Jacques Monod, and further elucidation of the
workings of the E.coli lac operon (again spearheaded by Monod, for which he and
François Jacob were awarded the 1965 Nobel Prize in physiology) highlight the fact that
reversible, non-covalent binding is paramount to the activity and regulation of the
molecular functions that make life possible.
Countless examples of reversible binding abound in biology. These include (but
are not limited to) gene expression, metabolic regulation, signaling across membranes,
self/non-self recognition, intercellular communication, interaction of organisms with their
environment, and antigen-antibody interaction. In each of these examples, reversible
binding provides a means for intricate control of the biological process (Figure 1-1).
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Figure 1-1
Examples of reversible interactions important to life.
A. Competitive binding in enzyme catalysis. Reversible binding of an inhibiting
molecule to the active site of an enzyme precludes binding of the intended substrate
and prevents progress of the reaction. The reversible nature of the binding allows
for the reaction to proceed as the concentration of the inhibitor decreases. B.
Control of the lac operon. A repressor molecule prevents the binding of RNA
polymerase to the lac gene and forestalls the synthesis of mRNA. Reversible binding
of lactose alters the affinity of the repressor for the operator sequence, which
reverses the blockage and allows lactase synthesis to proceed. C. Notch-mediated
juxtacrine signal between adjacent cells. Reversible binding of the cell surface
protein Notch to a Notch receptor (Delta) on an adjacent cell initiates a cascade of
metabolic consequences. The precise binding ensures that only the two cells respond
to each other’s proximity in a very specific manner. D. Control of glucose transport
by insulin. The activity of glucose transporter-4 is carefully controlled by the
activity of the insulin receptor, which is in turn finely tuned by the reversible
binding of insulin.
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In each case, a strong permanent binding would result in a binary, on/off control
switch. The elegance of reversible binding is that intermediate control can be attained,
depending on the strength of the interaction and the concentration of the reactants2.
Consider the reversible binding of a ligand (L) to its receptor (R). The
bimolecular reaction may be represented as

Another representation is
kon
𝑹𝑹 + 𝑳𝑳

koff

𝑹𝑹𝑹𝑹

At equilibrium, the rate of association and dissociation of the complex are equal,
proportional to the concentration of reactants and the rate constant in each direction:
𝑘𝑘𝑜𝑜𝑜𝑜 [𝐿𝐿][𝑅𝑅] = 𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜 [𝐿𝐿𝐿𝐿]

(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 1)

The concentrations of the reactants are, therefore, in a dynamic steady state.

Equation 1 can be rearranged to establish the ratio of reactants to products at equilibrium,
𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜 [𝐿𝐿][𝑅𝑅]
=
[𝐿𝐿𝐿𝐿]
𝑘𝑘𝑜𝑜𝑜𝑜

At equilibrium, the association constant, KA, is defined as
𝐾𝐾𝐴𝐴 =

[𝐿𝐿𝐿𝐿]
𝑘𝑘𝑜𝑜𝑜𝑜
=
[𝐿𝐿][𝑅𝑅] 𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜

while its reciprocal, the dissociation constant, KD, is

(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 2)

(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 3)
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[𝐿𝐿][𝑅𝑅]
𝑘𝑘𝑜𝑜𝑜𝑜𝑜𝑜 (𝑠𝑠 −1 )
1
𝐾𝐾𝐷𝐷 (𝑀𝑀) = �𝐾𝐾 =
=
𝐴𝐴
[𝐿𝐿𝐿𝐿]
𝑘𝑘𝑜𝑜𝑜𝑜 (𝑀𝑀−1 𝑠𝑠 −1 )

(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 4)

In common usage, KD is referred to as the affinity, in units of molarity. The

smaller the magnitude of KD, the greater the affinity, i.e., a molecule with a KD of 1 nM
has 1000 times greater affinity than one of 1 µM.
The Importance of Affinity
In molecular biology, the affinity of a ligand for its receptor is directly related to
its activity. In medicine, small molecule drugs or antibodies often exert their therapeutic
action by inhibiting or activating a receptor, and, likewise, the activity and efficacy of the
drug is directly related to its affinity for the receptor3. In biological science, a reagent is
more potent when it has a higher KD for its target. As can be seen from Equation 3, [LR]
is maximized when the association rate constant, kon, is greater than the dissociation rate
constant, koff4.
Zuckier et al.5 investigated the visualization of beads (as surrogate for cellular
antigens) coated with high or low density of antigen, with radiolabeled antibodies of
various affinities. They demonstrated in their mouse tumor model an inverse relationship
between the affinity of an antibody and the amount of antibody needed to visualize the
beads. Beads coated with the lowest density of antigen could be best observed with
antibodies of high affinity.
A number of studies have found a correlation between affinity and effectiveness
in vivo and in vitro. Liddament6 studied the efficacy of monoclonal antibodies against
interleukin-5a in a human-IL-5-dependent cell proliferation assay. Those monoclonal
antibodies (mAb) with greater affinity for IL-5 also exhibited greater cell proliferation
activity in vitro. Li et al.7 investigated the efficacy of antibodies of varying affinity to
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protect SCID mice a infected with the intracellular bacterium Ehrlichia chaffeensis. They
concluded that, “Although it is not known whether high affinity is essential, it was the
most important correlate of efficacy.” Zhu et al.8 found correlation between antibody
affinity and the inhibition of human leukemia in an animal model, using human
antibodies directed against vascular endothelial growth factor receptor 2 (VEGF2). Mice
treated with antibody of the highest affinity survived longer than those treated with
antibodies of lesser affinity.
There may be limits to the affinity-activity paradigm, as increased affinity may
actually impede the penetration of a therapeutic agent to its target, such as a tumor mass9.
Adams et al.10 found that affinities greater than one nM offered no further advantage to
the penetration of single-chain variable antibody fragments into a mouse tumor model.
Principles of KinExA Operation
A number of methods exist to measure the various parameters of Equation 4,
including surface plasmon resonance (SPR) and enzyme-linked immunosorbent assay
(ELISA). The KinExA line of biodetectors was introduced by Sapidyne, Inc. (Boise, ID)
in 1995 as an alternative to these and other methods. The salient operating principle of
KinExA, which also affords its chief advantage, is that the ligand and receptor may be
contacted in true solution. This feature avoids any perturbation of the equilibrium due to
the proximity of any feature of the immobilizing matrix11–22. It also avoids conflation in
the kinetic measurements of intrinsic affinity with limitations due to mobility of the
molecules in the solution23,24. The detection method is highly accurate and repeatable
with a large dynamic range25,26. It has been shown in multiple comparisons to be superior

a

Severe combined immunodeficient mice lack B and T cells.
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to SPR and ELISA in accuracy, sensitivity, versatility, and reliability11,15,16,25,27–29.
Molecular weight of the analyte poses no limitations24,28,30, as it has been employed in
studies ranging from ions28,30 and small molecules18,31,32, to whole cells16,27,31,33. In
addition, no separations are necessary. This can be a great advantage, both for logistical
considerations for the experiment, and for the system itself. Amizadeh and Van
Regenmortel34 showed that physical separation of a bivalent reactant, like an antibody,
also removes the second reactant site, which may be unoccupied, and important
information can be lost. In the KinExA system both binding sites of the antibody remain
available for capture, but must be accounted for in the analysis35.

Figure 1-2.

A. KinExA 3200 with autosampler. B. KinExA 4000. C. Flow cell
camera

Two models of the KinExA apparatus are shown in Figure 1-2. The key
component of the KinExA apparatus is a flow cell (Figure 1-2C) approximately 8 µL in
volume, packed with beads functionalized to react with one partner of a reversible,
bimolecular reaction (capture beads). The total surface area is over 2.5 cm2, with a void
volume of roughly 4 µL. A sophisticated fluid handling system delivers reagents to the
flow cell with precise timing, while a highly sensitive epifluorescent illumination and
detection system provides the signal for analysis (Figure 1-5). The capture beads are
delivered to the flow cell, and the analytical solution is flowed over the cell. The beads
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are functionalized so that only free molecules will be bound to the beads. These
molecules may be fluorescent themselves, or are subsequently exposed to fluorescent
secondary labels, and the fluorescent signal is a function of concentration (Figure 1-3)36.
By knowing initial conditions, the amount of free molecule can be measured, and kinetic
parameters calculated, as further detailed below.
The typical KinExA experiment consists of three parts. First is preparation of the
functionalized beads which will capture the analyte for measurement (Figure 1-3).
Second is preparation of a series of solutions consisting of a constant initial concentration
of one component of the binary reaction and serial dilutions of the other reactant (Figure
1-4). The component that is kept constant is the constant binding partner (CBP), and is
the one which will be analyzed. Third, each reaction mixture is sampled and the
fluorescence of free CBP bound to the capture beads is obtained for subsequent
numerical analysis.
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Figure 1-3. Diagram of bead preparation and labeling for signal generation
An equilibrium mixture of a constant binding partner (CBP) and its ligand (L) will
exist as free CBP, free L, and some proportion of bound L-CBP (A). When this
mixture is flowed over beads derivatized with the ligand, a proportion of the free
CBP will bind to the ligand on the beads (B). If necessary (e.g., when CBP is not
fluorescent), a fluorescent label can be attached to the bead-bound CBP to generate
the eventual analytical signal (C).
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Figure 1-4. Schematic principles of equilibration step.
A series of mixtures is prepared with one component at the same concentration in
all of the mixtures (constant binding partner, or CBP), while the other reactant is
present in serial diluted in concentrations ranging two orders of magnitude or more.
After equilibration, most of the CBP in the low-L mixture is still in its unbound
state, while very little free CBP exists in the high-L mixture. The concentration of
CBP in the intermediate mixtures provides information between the extremes for
numerical analysis.
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Figure 1-5. Conceptual flow diagram of the KinExA biodetector.
Samples and reagents are delivered to the flow cell detection system through a series
of tubing, valves and pumps. Beads are first loaded to the flow cell. Samples are
then passed over the beads, where a proportion of unreacted (free) molecules from
the sample mixture are captured. If necessary, visualization reagent (fluorescentfunctionalized antibody, HIS tag, etc.) is then passed over the beads. Fluorescence of
the bound molecules are measured with a photodetector.
A number of detection schemes have been used, most frequently fluorescent
labeled secondary antibody. A common use of the KinExA platform is the evaluation of
the affinity of mAb36,37. In a setting producing antibodies from a single species, say,
mouse, a routine protocol can be established using the same secondary antibody, say,
goat anti-mouse IgG, for all assays. In some cases, the analyte may be a protein modified
with biotin, which can be detected with fluorescent avidin. Proteins labeled with
polyhistidine (His-tag) can be visualized with fluorescent anti-His antibody, but results
can vary38.
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Burden et al. (in press) measured the KD of the fluorophore RNA mango as it
bound to immobilized biotin on the bead surface. The fluorescence response of this
aptamer to photoexcitation is several orders of magnitude greater when bound to biotin
than when unbound. We herein39 used a fluorescent anti-thrombin single-stranded DNA
aptamer to investigate aptamer-thrombin binding, and to propose an aptamer-based
procedure to measure biomolecules (see Chapter 2).
The KinExA Sensogram
The fluorescence detected in a given moment in the flow cell is the sum of the
fluorescence present in the fluid being passed over the beads, plus the fluorescence of the
analyte captured on the surface of the beads themselves. This can be best illustrated by
comparing the sensograms of two different experiments differing in the manner of
visualization.
In our thrombin aptamer experiments, detailed later in this dissertation, the
analyte was an aptamer labeled with Alexa Fluor 647, so that it constantly generated a
fluorescent signal to the photodetector. In these experiments, thrombin and a singlestranded DNA (ssDNA) anti-thrombin aptamer were mixed together and allowed to come
to equilibrium. These beads would only capture aptamer which was not complexed with
thrombin. The equilibrium mixture was then passed over beads which had been coated
with a polynucleotide complementary to the anti-thrombin aptamer. The detector
response increased monotonically as the sample passed over the beads and a portion of
free aptamer bound to the beads. Once the sample had been delivered and a rinsing
solution was introduced, the rinse solution no longer contributed to the fluorescence, and
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the fluorescence was due only to bound aptamer (Figure 1-6). Similar traces were
observed with labeled primary antibodies to biotin, challenging biotin-coated beads36.

Figure 1-6. The fluorescent signal.
Thrombin and a ssDNA anti-thrombin aptamer were mixed together and allowed to
come to equilibrium. Beads coated with a polynucleotide complementary to the antithrombin aptamer captured only aptamer which was not complexed with thrombin.
The resulting sensogram suggests that most of the free aptamer was captured, as
there is only a slight decrease in fluorescence once the rinse solution is introduced.
In the mixtures, the labeled anti-thrombin aptamer was held constant (the CBP)
while the concentration of thrombin was varied as threefold dilutions. At the highest
thrombin concentration, the equilibrium solutions contained the least free aptamer,
while at very low thrombin concentrations most of the aptamer remained free.
KinExA experiments are more commonly performed by binding unlabeled free
CBP to the beads, followed by a visualization step, typically labeling with a specific
fluorescent antibody. Under these circumstances, the outward appearance of the
sensogram is significantly different, while the eventual information is the same. Figure 17 depicts a sensogram under these circumstances. Here, a mouse anti-digoxin antibody
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was mixed with serial dilutions of digoxin and brought to equilibrium. These equilibrium
solutions were flowed across beads functionalized with digoxin, which captured the free
antibody. This step was followed with a fluorescently labeled goat anti-mouse IgG
antibody, and a final buffer rinse. The final fluorescence is proportional to the bound
antibody, which is inversely proportion to the digoxin present in the equilibrium
solutions.

Digoxin
3.5

Fluorescence, Volts

3
2.5
2
1.5
1

200

250

300

350

400

450

Time (s)

Figure 1-7. Sensogram with secondary label.
In this instance, an anti-digoxin antibody was used to quantify digoxin. Mouse
antibody and dilutions of digoxin were mixed and brought to equilibrium. The
equilibrium solutions were flowed across beads functionalized with digoxin, which
bound the free antibody. This was followed with a labeled goat anti-mouse IgG
antibody and a final buffer rinse. The change in the curve at the red arrow indicates
the introduction of fluorescently labeled secondary antibody; and the change in the
curve at the blue arrow indicates the end of labeled secondary antibody and
commencement of a buffer wash. The final fluorescence represents the bound
antibody, in inverse proportion to the digoxin challenge.
A notional superposition of these two circumstances is depicted in Figure 1-8.
Here, it can be seen that regardless of the manner of fluorescent visualization, the final
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photocell response corresponds to the amount of analyte captured by the beads, in turn
proportional to the concentration of free analyte in the equilibrium mixture.

Figure 1-8. Notional time sequence of the KinExA sensogram.
Equilibrated solution is injected into the apparatus at time 1, and reaches the flow
cell at time 2. The dashed line denotes the analyte being captured on the surface of
the beads in the flow cell, and also corresponds to the photocell response for a
labeled analyte, such as a primary antibody or fluorescent aptamer. By time 3, the
analyte is fully loaded on the beads. The solid line represents the introduction of a
visualizing agent at this point, such as a labeled secondary antibody. The
fluorescence is due to the presence of fluorophore both in free solution and attached
to the bound analyte. At time 4, a rinsing buffer reaches the flow cell, removing the
free visualizing agent. The fluorescence eventually stabilizes and its value at time 5
is the data point.
Theoretical Foundation
The fundamental principle of kinetic exclusion is predicated on the premise that,
as long as koff << kon, then dissociation of a bimolecular complex into its component
entities contributes a negligible amount of unbound molecule during the brief period of
contact with the beads in the flow cell. If that is the case, then the signal is proportional
only to the free molecule (say, L) in the solution being analyzed.
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Equation 4 can be rearranged to give
[𝐿𝐿] =

𝐾𝐾𝐷𝐷 [𝐿𝐿𝐿𝐿]
[𝑅𝑅]

Invoking the conservation of mass, we find that

and

(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 5)

[𝐿𝐿] = [𝐿𝐿]0 − [𝐿𝐿𝐿𝐿]

(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 6)

[𝑅𝑅] = [𝑅𝑅]0 − [𝐿𝐿𝐿𝐿]

(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑖𝑖𝑖𝑖𝑖𝑖 7)

Combining these three equations and solving the resulting quadratic for [R] gives

[𝑅𝑅] =

2

𝑅𝑅0 − 𝐾𝐾𝐷𝐷 − 𝐿𝐿0 + �[𝑅𝑅]0 + 2[𝑅𝑅]0 𝐾𝐾𝐷𝐷 − 2[𝑅𝑅]0 [𝐿𝐿]0 + 𝐾𝐾𝐷𝐷 2 + 2[𝐿𝐿]0 𝐾𝐾𝐷𝐷 + [𝐿𝐿]0
2

2

A step-wise derivation of this equation can be found in the KinExA user

(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 8)

manual40.
The fluorescence detected by the instrument detector (in volts, V) is linearly
proportional to the receptor concentration, [R]36, which allows us to describe the
relationship

where

𝑉𝑉 =

(𝑉𝑉100% − 𝑉𝑉0% )
[𝑅𝑅] + 𝑉𝑉0%
[𝑅𝑅]0

(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 9)

V = voltage for [R]
V0% = voltage when there is no R in the solution
V100% = voltage when there is no L in the solution.
Substituting Equation 8 for [R] in Equation 9 gives the equation for the signal
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 = 𝑉𝑉0% +

𝑉𝑉100% − 𝑉𝑉0%
�([𝑅𝑅0 ] − [𝐾𝐾𝐷𝐷 ] − [𝐿𝐿0 ]) + �𝑅𝑅0 2 + 2[𝑅𝑅0 ]𝐾𝐾𝐷𝐷 − 2𝑅𝑅0 𝐿𝐿0 + 𝐾𝐾𝐷𝐷 2 + 2[𝐿𝐿0 ]𝐾𝐾𝐷𝐷 + 𝐿𝐿0 2 �
2[𝑅𝑅0 ]

(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 10)
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[L]0 is known from initial conditions, and [R]0, KD, V100% and V0% are determined
with aid of KinExA software that minimizes the squared error between the theoretical
data curve and the measured data27.
The Theory Curve
As one varies the initial concentration of receptor ([R]0) in a series of
experiments, while keeping [L]0 constant, a set of data can be accumulated corresponding
to Equation 11.
[𝑅𝑅]
=
[𝑅𝑅]0(𝑥𝑥)

[𝑅𝑅]0 − [𝐿𝐿]0 − 𝐾𝐾𝐷𝐷 + �[𝐿𝐿]0 2 − 2[𝐿𝐿]0 [𝑅𝑅]0 + 2[𝐿𝐿]0 𝐾𝐾𝐷𝐷 + [𝑅𝑅]0 2 + 2[𝐿𝐿]0 𝐾𝐾𝐷𝐷 + [𝑅𝑅]0 2 + 2𝐾𝐾𝐷𝐷 [𝑅𝑅]0 + 𝐾𝐾𝐷𝐷 2
2[𝑅𝑅]0
(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 11)

In our discussion, which binding partner is the ligand and which the receptor is
ambiguous, as it could go either way. In KinExA parlance, the partner which is kept
constant throughout the experiment is called the “constant binding partner” (CBP). The
equations above could have been derived for [L] with no material difference. When this
data set is plotted in a semi-log fashion, a theory curve can be generated like that shown
in Figure 1-941. Simultaneous iterative solutions of the data set, minimizing the squared
error between the theoretical data curve and measured data, will best fit the curve to the
data (example, Figure 1-9).
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Figure 1-9. Determination of KD from signal data.
Data collected as described in the text was fit to a least squares model of Equation
11. The KD value of 0.14 nM is shown by the vertical dotted line24.
The iterative curve-fitting algorithm integral to the KinExA software is also
capable of determining the confidence interval for the calculated KD, and the amount of
CBP that is active in solution (Figure 1-10). This information is valuable not only to
establish the precision of the measurements, but to alert the user to possible anomalies in
the reaction system (see below).
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Figure 1-10. Error Curves.
The KinExA curve-fitting software calculates error curves for both KD (left) and
percent activity of the CBP (right). For each data point represented in Figure 1-9, a
fit is performed by fixing the variable (KD) and by determining the other variables
([CBP], Signal0%, and Signal100%) by best fit. The standard deviation calculated by
this process is then divided by the value of KD obtained independently in order to
generate the percent variation. The error curve for percent activity is determined in
similar fashion, except that [CBP] is fixed. The 95% confidence intervals for KD and
[CBP] are denoted by the gray regions24.
The shape of the curve reflects the concentration of the CBP relative to the KD of
the bimolecular reaction. The slope of the sigmoidal curve increases as the concentration
of the CBP increases (Figure 1-11, Sapidyne simulation42). The most accurate estimate of
KD will be obtained when [CBP] = KD. When [CBP] < KD, the slope of the curve will
decrease, and the curve is said to be a “KD controlled curve.” The slope and shape of the
curve will not change appreciably below [CBP] = 0.20KD. At low ratios an accurate KD
measurement may be obtained, but the uncertainty in [CBP] will be high. To the right of
KD in the graph, increasing [CBP] will increase the slope of the curve and also shift it to
the right, conditions described as “concentration controlled.” In this region, an accurate
measurement of [CBP] can be obtained at the expense of certainty in measured KD.
Exceeding [CBP] = 5KD will move the measurement of [CBP] into the shoulder of the
curve and reduce reliability.
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Figure 1-11. Simulation of theory curve in relation to the ratio of KD to CBP.
In this instance, KD is 100 pM. For the blue curve, CBP = KD. For the red curve,
CBP is 10% of KD, or 10 pM, while the green curve represents the situation where
CBP = 10 x KD42.
N-Curve Analysis
In a new experiment, KD is not known a priori. It is therefore recommended that
two or more dilution series be prepared at a range of [CBP]12,33,37,43. KinExA software
allows simultaneous analysis of the data with its “n-curve analysis” module42.
Two or more data sets for the same bimolecular system are loaded into the
module, differing only in the concentration of the CBP. The analytical algorithm will
constrain the difference in CBP values for the curves to those that are input, and then
apply the data to find the best fit for all the curves loaded (Figure 1-12). The analysis will
usually result in narrower confidence intervals, and anomalies can suggest to the operator
on off-model behavior, such as cooperativity (see below).
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Figure 1-12. N-Curve analysis.
Albumin competes with LT3015 (an anti-lysophosphatidic acid (LPA) monoclonal
antibody for binding the various lysophosphatidic acids. Here, the competition of
albumin with monounsaturated form is analyzed with KinExA 4-curve analysis.
Antibody was kept constant at 1 nM, and brought to equilibrium with serial
dilutions of LPA(18:1) in the presence of varying concentrations of fatty acid-freeBSA: blue 3 µM, green 30 µM, orange 150 µM, and pink 300 µM. The n-curve
analysis shows that the response curves shift toward higher lipid concentrations in
response to the BSA sequestering the LPA(18:1). Fitting any of these curves in the
absence of the additional information would result in an incorrect estimate of the
LT3015-LPA(18:1) KD value21.
KinExA Mode
As noted above, the fundamental principle which enables KinExA technology is
that koff << kon. If such is the case, then the system is said to be operating “in the KinExA
mode44.” This condition can be verified by running samples at different flow rates. A
“tight” system (koff << kon) will exhibit a constant signal at all flow rates, while a “weak”
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system will exhibit a decreasing signal as flow rate increases (Figure 1-13)45. If a flow
rate can be established where a plateau of signal is reached (red curve in Figure 1-13),
then that flow rate is appropriate for ensuing experiments.
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Figure 1-13. The KinExA mode.
Comparison of KinExA data analysis for a “tight” system (koff << kon) and a “weak”
system where such is not the case. The tight system will exhibit a constant signal at
all flow rates, while a “weak” system will exhibit a decreasing signal as flow rate
increases. The flow rate for the weak system should be set where the response is
observed to plateau44.
The consequence of an insufficient flow rate for the system will be an erroneously
weak KD (Figure 1-14).
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Figure 1-14. Effect of flow rate on a weak binding bimolecular pair.
For a weak binding pair, a significant portion of bound partner is washed from the
capture element at slower flow rates, leading to a false measurement of CBP in the
equilibrated solution. Analyses should be conducted at flow rates where further
increases in rate do not change the signal44.
Cooperativity
In many biological systems, the binding of a ligand can result in morphological
changes that alter the activity of a remote portion of the molecule. This allosteric change
can confer greater or lesser activity. For 5-10% of antibodies, even though each arm of
the bivalent molecule is identical, the binding of one ligand can increase the affinity of
the other arm for that ligand46–48. In such a case, the usual binding model is insufficient,
but anomalies can be recognized and dealt with49,50.
Under these circumstances, there are two populations of molecules with different
affinities for the ligand: the native antibody, and the antibody with one ligand attached
(Figure 1-15).

23

Figure 1-15. Cooperativity.
The identical arms of a bivalent antibody usually have equal affinity for its ligand
(KD1 = KD2), but a significant fraction of antibodies exhibit cooperativity, where
binding of one ligand changes the affinity of the free arm (KD1 ≠ KD2)50.
The descriptive equilibrium equations are as follows. The affinity constants for
the ligand and the unbound and singly bound antibody are given by equations 12 and 13,
respectively, and the mass balances for each reactant in equations 14 and 15.
𝐾𝐾𝐷𝐷1 =
𝐾𝐾𝐷𝐷2 =

[𝐿𝐿][𝑅𝑅]
[𝐿𝐿𝐿𝐿]

[𝐿𝐿𝐿𝐿][𝑅𝑅]
[𝐿𝐿𝐿𝐿𝐿𝐿]

𝑅𝑅𝑇𝑇 = 𝑅𝑅 + 2𝐿𝐿𝐿𝐿 + 𝐿𝐿𝐿𝐿𝐿𝐿

𝐿𝐿 𝑇𝑇 = 𝐿𝐿 + 2𝐿𝐿𝐿𝐿 + 2𝐿𝐿𝐿𝐿𝐿𝐿

(Equation 12)
(Equation 13)
(Equation 14)
(Equation 15)

Potential cooperativity can be suspected by significant deviation of reported KD
and percent activity of a system investigated at two different CBP. The data points can
also suggest a different slope than the calculated best fit (Figure 1-16).
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Figure 1-16. Suspicious activity calculations.
On the left, the reported percent activity of the CBP is an impossibly high 187%. On
the right, an n-curve analysis of relatively high (red) and low (blue) CBP reports a
more reasonable percent activity of 75%. In addition, the data points on the blue
curve seem to suggest a steeper slope for the theory curve than what is reported50.
Invoking a cooperativity model to the data resolves the discrepancy, resulting in a
markedly better fit of the data to theory (Figure 1-17) The parameters returned from the
model report an effective dissociation constant (KDEFF) along with a value for the Hill
coefficient b, a measure of cooperativity, where
𝐾𝐾𝐷𝐷1 =
𝐾𝐾𝐷𝐷2 =

(𝐾𝐾𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 )(𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 )
(2 − 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 )

(𝐾𝐾𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 )(2 − 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 )
(𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 )

(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 16)
(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 17)

The Hill coefficient (n) indicates the degree of cooperativity. A value of 1 denotes no cooperativity. A
value n > 1 denotes positive cooperativity, while n < 1 denotes negative cooperativity. See discussion on
concentration measurements, below.

b

25

Figure 1-17. N-curve analysis for a system exhibiting positive cooperativity.
The theory curve fit to the data is markedly better than seen in Figure 1-16. The
parameters returned from the model report an apparent dissociation constant
(effective KD), as well as a Hill coefficient for the system, from which the separate
dissociation constants of the native and allosterically modified antibodies can be
derived (see text)50.
Conformational change resulting in allosteric binding behavior of antibodies may
extend into the Fc region of an antibody47. Since antibodies directed against the constant
region are commonly used to immobilize the antibody being analyzed, (e.g., SPR),
unsuspected cooperativity may account for differences in KD measurements between
KinExA and SPR50.
Whole Cell Analysis
KinExA is well suited to the analysis of whole cells, both for affinity
measurements and to determine receptor density on the surface of cells16,27,31,33,51. CBP
and whole cells can be mixed and allowed to come to equilibrium, then separated
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gravimetrically. Only unbound CBP will remain in solution and analysis is
straightforward.
The expression level of an antigen on the surface of a population of cells may be
denoted by

where:

𝐸𝐸𝐸𝐸 =

𝐶𝐶 × 𝑇𝑇𝐴𝐴 × 𝑁𝑁𝐴𝐴
1000 × 𝑇𝑇

(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 18)

EL: expression level (molecules per cell)
C: antigen level/cell; a reasonable but arbitrary value52 is 103 - 106
TA: antigen activity level, determined by KinExA software
NA: Avogadro’s number (6.02 x 1023/mol)
1000: convert mL to L and align units
T: Total cells/mL
Using this relationship, and n-curve analysis, Xie et al.27 found the abundance of
human insulin-like growth factor I receptor to be between 6 x 106 and 5 x 107/cell.
Rathanaswami et al.33 determined the KD of an antibody and integral surface proteins, by
analyzing residual free antibody in solution to KinExA after equilibrium had been
established between the antibody and whole cells.
Concentration Measurements
The unknown concentration of a ligand may be determined by creating a standard
curve of voltage response to known concentrations and comparing the unknown to that,
but the same principles that are used to generate the theory curve can be used to evaluate
the unknown. The KinExA software package will generate the binding curve by
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averaging and fitting with a four-parameter logistic equation, whereby the signal, as
defined in Equation 19, is a function of concentration26,36,39,53:
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 =

𝐵𝐵1 − 𝐵𝐵2
+ 𝐵𝐵2
𝑥𝑥 𝐵𝐵4
1 + �𝐵𝐵 �
3

(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 19)

where B1 is the upper asymptotic plateau (maximum signal), B2 is the lower asymptotic
plateau (NSB), B3 is the inflection point (the concentration at which the signal is halfway
between the extreme values), B4 is the Hill coefficient (slope)54, and x is the titrant’s
concentration.
The same equation, rearranged to solve for x, allows calculation of the unknown
concentrations from the corresponding signals:
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 − 𝐵𝐵
𝑙𝑙𝑙𝑙 �𝐵𝐵 − 𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆1 �
2
[𝑥𝑥 ] = 𝑒𝑒𝑒𝑒𝑒𝑒 �
� ∙ 𝐵𝐵3
𝐵𝐵4

(𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 20)

Rathanaswami et al.55 were able to measure serum levels of interleukin 13 (IL13)
in serum samples, using a specific anti-IL13 and when no IL13 standards were available,
i.e., using only the minute amounts of IL13 available in the serum. By challenging
identical concentrations of the anti-IL13 with various dilutions of serum and applying ncurve analysis, both KD and [IL13] could be determined (Figure 1-18).

28

Figure 1-18. KD measurements of anti-human IL13 (hIL13) mAb to native hIL13.
Human anti-hIL13 mAb was serially diluted 1:3 from a binding site concentration
of 25 nM to 42 fM and incubated with 11x (curve 1), 22x (curve 2), 275x (curve 3),
or 550x (curve 4) diluted hIL13 conditioned medium generated from CD8-depleted
peripheral blood mononuclear cells. After 72 hours of equilibration, the free hIL13
present in the equilibrium mixtures was measured using mAb-coated PMMA beads
and detected with a Cy5-labeled secondary antibody. The percentage free hIL13 was
determined with KinExA n-curve analysis software. Optimal values for KD and the
native hIL13 concentration were determined by n-curve analysis55.
Blake et al. have employed KinExA to analyze mAbs which were directed toward
specific metal chelates56–58. A prototype KinExA protocol was able to detect Pb(II) in a
spiked groundwater sample down to 6 nM, a level that was beyond the feasible limit of
detection for a corresponding ELISA protocol28.
Kinetics Measurements
The progress of a reaction (kinetics) can be directly observed by choosing
“Kinetics Direct” as the experiment type from the KinExA protocol menu. Because of the
bead handling and sample loading routines, successive data points will necessarily be five
minutes or more apart. For a relatively slow reaction, that may be satisfactory. If
equilibrium is substantially achieved within this time frame, early data points must be
obtained in separate experiments with manual mixing, and the data combined gathered
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together for analysis59. Kinetic parameters kon, koff, and KD (equations 1-4) will all be
determined by best fit to the mathematical model.
Comparison to Other Methods
Several other methods are available to measure molecular interactions, notably
surface plasmon resonance (SPR, commercially available from Cytiva under the trade
name Biacore, or more recently by Carterra as LSA); isothermal titration calorimetry
(ITC; commercially available from TA Instruments and Microcal/Malvern Instruments);
and enzyme-linked immunosorbent assay (ELISA, widely available).
Surface Plasmon Resonance
The operating principle of SPR is shown in Figure 1-20. The change in refractive
index imparted by binding of an analyte to a thin film of gold on one surface of a prism is
detected by a beam of light directed on that surface. By measuring the spectrum shift of
the beam of light, the concentration of analyte can be measured, and the progress of the
binding reaction can be followed in real time. The method is sensitive to about 10
pg/mL60. The required immobilization of one ligand in the Biacore system could be
problematic, especially for small molecules, if the immobilization scheme interferes with
the binding site. Since SPR depends on binding directly from the analytical solution,
mass transfer limitations, especially for large molecules with high association rate, may
obscure the observation of actual KD. These limitations may be overcome by careful
manipulation of the flow conditions or by including a mass transport term in the data
fitting step. In terms of cost, the Biacore equipment can cost 3-4 times as much as
KinExA, and the cost of Biacore chips is quite high. The Biacore may be configured to
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have a higher throughput than KinExA, which may offset the high cost in appropriate
circumstances24.

Figure 1-19. Operating principle of surface plasmon resonance.
A thin metal film (typically gold) is evaporated onto the surface of a high-reflective
index glass prism. Biorecognition molecules are attached to the gold film, and that
surface is brought into contact with the solution to be analyzed. The refractive index
of the gold layer is acutely sensitive to the attachment of analyte to the
biorecognition elements, which can be detected by a shift in the wavelength of light
shone through the prism onto the gold-coated surface c,d. Lower right: Solution
containing analyte is flowed over the detector and the change of refractive index can
be followed as a function of time to directly measure the progress of the
equilibration e. Subsequently flowing an analyte-free solution reveals the progress of
dissociation. The association and dissociation constants can thus be directly
measured, and KD calculated by Equation 3.
Drake et al.12 performed an extensive study comparing Biacore and KinExA
analyses with regards to dextran density on the Biacore chip used in the analysis. Biacore
chips can be obtained pre-coated with carboxymethylcellulose (CM). Although the

Diagram by Sari Sabban - Sabban, Sari (2011) Development of an in vitro model system for studying the
interaction of Equus caballus IgE with its high- affinity FcεRI receptor (PhD thesis), The University of
Sheffield, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=18139885
d
By Original uploader was Tomio- at en.wikipedia - Transferred from en.wikipedia, CC BY-SA 3.0,
https://commons.wikimedia.org/w/index.php?curid=9881864
e
Figure from Narayanese at the English Wikipedia, CC BY-SA 3.0,
https://commons.wikimedia.org/w/index.php?curid=9881873
c

31
absolute value of CM on a chip is proprietary information, they were able to estimate
relative values from other available information. They determined that the CM4 chip
contains approximately 30% of the CM as the standard CM5 chip, while the C1 chip
(while not having any dextran layer) has about 10% of that amount of carboxyl groups.
By preparing analytical chips by amine coupling of the Ag to the carboxyl groups on the
surface of the chip, and observing the KD values returned by the SPR protocol, they noted
that as the relative carboxyl density decreased, the reported KD approached that
determined by KinExA solution-phase analysis (Figure 1-20). Liddament6 measured the
affinity of two mAbs using both KinExA and Biacore. While they found the relative
affinities of the two antibodies to be the same by both methods, they found KinExA
analysis returned absolute KD values approximately 10-fold lower than Biacore, which
they attributed to surface effects for the Biacore method without further investigation.
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Figure 1-20. Surface effects on Biacore analyses.
As dextran (carboxyl) density decreased on the Biacore chips used to perform the
assay, the reported KD decreased, approaching the value reported by the purely
solution-phase KinExA assay12.
A recent study by Brown61 compared the response of newer SPR flat chips to the
ones studied by Drake, and found a closer correlation to true solution kinetics. It is
instructive to note that the standard of comparison was the KinExA.
Isothermal Calorimetry
ITC is based upon measuring the heat released or absorbed as a reaction
proceeds62 (Figure 1-21). The apparatus consists of an adiabatic chamber containing a
reaction cell and a reference cell. A bolus of analyte is delivered to a solution of its
ligand, and the resulting heat released to or absorbed from the chamber is monitored. It is
universally applicable to any reaction in solution, without any labeling or other chemical
modification to the reactants required in order to facilitate detection. There are no
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molecular weight limitations. Instrument analytical software can determine the change in
enthalpy (ΔH), binding constant KD and fractional saturation (n), from which the Gibbs
free energy and entropy change can be calculated from the relationships ΔG = nRTlnKD
= ΔH -T ΔS, where R is the universal gas constant, and T is the absolute temperature.
Disadvantages of the technique are the relatively large quantities of reactants required,
and the fact that the reactants must be quite pure. Reactants must also be stable and
sufficiently soluble to provide enough mass to generate a signal. Sensitivity is sufficient
to measure KDs in the millimolar to low nanomolar range, several orders of magnitude
less sensitive than KinExA24,62,63. Darling and Brault24 found that, while the ITC
apparatus costs just a bit more than KinExA, due to the large quantities of reagents
required, the cost of consumables in comparison to KinExA is quite high.

Figure 1-21. Basic schematic illustration of the isothermal titration calorimeter
instrument.
A sample and reference cell are contained within an adiabatic chamber. Analyte is
injected into the sample cell, which contains the ligand to the analyte, and the heat
released or consumed by the reaction is followed by monitoring the temperature and
heating requirements necessary to maintain the isothermal conditions, as compared
to the reference cell f. The top right panel shows the sequence of peaks, each of which
corresponds to an injection of the solution in the syringe. This example corresponds
f

Left, public domain, https://en.wikipedia.org/w/index.php?curid=6536395
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to an exothermic reaction. The bottom right panel shows the integrated heat plot.
The areas under each peak, calculated and normalized per mole of ligand injected in
each injection, are plotted against the molar ratio of reactants. Curve fitting to these
data can determine the thermodynamic parameters of KD, enthalpy, and
stoichiometry g.
Enzyme-Linked Immunosorbent Assay
ELISA is widely available in many variations from multiple manufacturers. In
general principle (Figure 1-22), a specific antibody is conjugated to an enzyme,
frequently horseradish peroxidase. This conjugated antibody is used to detect its antigen
in a manner proportional to its concentration. A plethora of variations abound, differing
in the way the analyte is initially captured, the way the enzyme linkage is introduced, and
detection method, and other iterations. In the first step of the process, the wells of a
multi-well plate are functionalized to capture the analyte. Then, solutions containing the
analyte are added to the wells, along with appropriate standards. Next, the bound analyte
is marked with the conjugated antibody, and an appropriate substrate is added to react
with the enzyme and generate a color for quantification. (Rinse steps are not described in
detail in the preceding discussion.) After an appropriate amount of time, the plates are
placed in a plate reader for analysis. Information may be obtained commensurate with the
other processes presented herein64. Darwish et al.65, compared KinExA competitive assay
to ELISA analysis of four cancer markers in biological specimens. They found KinExA
to have superior limits of detection by one to three orders of magnitude for three of the
four, while the detection limit for the fourth was roughly the same. They attributed the
difference to the inherent sensitivity of the KinExA system as well as to the fact that the

Right, by Simon Caulton - Own work, CC BY 4.0,
https://commons.wikimedia.org/w/index.php?curid=82487783
g
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antibody-antigen analytical mixture was allowed to come to equilibration for the KinExA
system, while the corresponding ELISA contact time was truncated to one hour in
accordance with the protocol used.

Figure 1-22. The operating principles of enzyme-linked immunoassay (ELISA).
The wells of a multi-well plate are functionalized so as to capture the analyte when
exposed. In this case, a virus particle has been captured, proportional to the amount
in the sample. This is followed by a virus-specific antibody which has been
conjugated to an enzyme, such as horseradish peroxidase (HRP), whose activity will
be used to generate the signal. A plethora of variations exist h. Right: An example of
a multi-well plate developed with HRP and the chromophore TMB, showing the
color gradient proportional to the analyte concentration i.
Glass et al. compared the sensitivity of KinExA, ELISA and SPR26. Four
antibodies to estradiol were evaluated, and experiments were performed by expert
technicians in the companies that manufactured the equipment. Least detectable
concentration and dynamic range were determined. Four antibodies specific to estradiol
were evaluated in an estradiol assay on each platform. The least detectable concentration
(LDC) and dynamic range (DR) of each platform were determined, as well as an estimate
of the KD of the interactions (Figure 1-23). The SPR biosensor was able to measure
inhibition curves for all four antibodies, but could measure KD for only two of the
antibodies. The other two antibodies provided insufficient response for KD estimation.

Diagram y Cavitri - Own work, CC BY 3.0, https://commons.wikimedia.org/w/index.php?curid=9627246
photo of plate By Ajpolino - Own work, CC0,
https://commons.wikimedia.org/w/index.php?curid=88819005

h
i
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The KinExA biosensor was able to measure inhibition and KD for all four antibodies.
Inhibition for all four antibodies was detectable by ELISA, but KD was elusive. In all
cases, KinExA provided superior sensitivity and range as compared to the other two
platforms.
The kinetic exclusion assay is an accurate, sensitive, versatile, and reliable
method to determine kinetic parameters for bimolecular interactions, and to determine
concentrations of analytes to minute quantities. In this study, we investigate further its
properties and potential for further use.

Figure 1-23. Comparison between SPR, ELISA and KinExA26.
Least detectable concentration (LDC), dynamic range (DR) and KD of SPR, KinExA
(KE) and ELISA challenged with four antibodies. Large open circles indicate the
measured KD for the antibody and technique. The vertical lines in panel A indicate
the range from lowest to maximum (i.e., usable range) detectable concentration,
calculated using three times the standard deviation. The vertical lines in panel B
show the LDC (minimum symbol) and DR calculated from noise theory. KD was not
obtainable if the open circle is missing.
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CHAPTER TWO: KINETIC EXCLUSION ASSAY OF BIOMOLECULES BY
APTAMER CAPTUREj
Abstract
DNA aptamers are short nucleotide oligomers selected to bind a target ligand with
affinity and specificity rivaling that of antibodies. These remarkable features recommend
aptamers as candidates for analytical and therapeutic applications that traditionally use
antibodies as biorecognition elements. Numerous traditional and emerging analytical
techniques have been proposed and successfully implemented to utilize aptamers for
sensing purposes. In this work, we exploited the analytical capabilities offered by the
kinetic exclusion assay technology to measure the affinity of fluorescent aptamers for
their thrombin target and quantify the concentration of analyte in solution. Standard
binding curves constructed by using equilibrated mixtures of aptamers titrated with
thrombin were fitted with a 1:1 binding model and provided an effective KD of the
binding in the sub-nanomolar range. However, our experimental results suggest that this
simple model does not satisfactorily describe the binding process; therefore, the
possibility that the aptamer is composed of a mixture of two or more distinct KD
populations is discussed. The same standard curves, together with a four-parameter
logistic equation, were used to determine “unknown” concentrations of thrombin in mock

This chapter was published as Smith MH, Fologea D. Kinetic Exclusion Assay of Biomolecules by
Aptamer Capture. Sensors (Basel). 2020 Jun 18;20(12):3442. doi: 10.3390/s20123442. PMID: 32570818;
PMCID: PMC7348807.
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samples. The ability to identify and characterize complex binding stoichiometry, together
with the determination of target analyte concentrations in the pM–nM range, supports the
adoption of this technology for kinetics, equilibrium, and analytical purposes by
employing aptamers as biorecognition elements.
1. Introduction
Aptamers are short nucleotide oligomers selected and isolated by the Systematic
Evolution of Ligands by Exponential Enrichment (SELEX) technique1–4 to present high
specificity and affinity for a large variety of targets ranging from ions5–8 and small
molecules9–12 to whole cells13–15. Their ability to selectively recognize and bind targets
recommends them as promising alternatives to antibodies for scientific and medical
purposes9,13,16–25. Aptamers have been investigated as potential analytical and diagnostic
tools with approaches and technologies that traditionally employ antibodies as
recognition elements. Compared to antibodies, DNA aptamers are cost effective, present
similar specificity and affinity for targets, have greater stability either lyophilized or in
solution at room temperature, and are readily amenable to chemical modifications17,25–28.
Numerous traditional and emerging analytical techniques have been proposed for
aptamer-based qualitative and quantitative assessments of molecular and cellular
interactions23,25,28–32. Aptamer-thrombin systems that use the 15-mer33 and/or 29-mer34
aptamer as biorecognition elements are among the most used in scientific investigations
focused on affinity and concentration determination29,35–41, which is justified by the
essential physiological role of thrombin42. Nonetheless, both aptamers are far from fully
characterized in terms of affinity and binding models35. For example, the reported affinity
of the 29-mer aptamer varies by more than four orders of magnitude, and is also strongly

46
dependent on the instrumental method and adopted binding model29,34–37,39–41. Only a few
studies reported affinities in the nM range40,41, close to the ~0.5 nM first reported by
Tasset34, while many others indicated affinities up to a few hundred times larger29,35–37,39. It
is not clear if such discrepancies originate in the instrumentation and mathematical
models employed, or whether particular experimental conditions and methodologies also
influence the measurements35. To better understand the aptamer-thrombin interactions and
pave the way towards analytical applications, we used the kinetics exclusion assay
(KinExA) technology, developed by Sapidyne, Inc. (Boise, ID, USA) to determine the
29-mer aptamer affinity for thrombin, and thrombin concentration in solutions.
This technology provides highly accurate analyses of molecular interactions in
true solution phase systems43–54. The principle of operation relies on specifically assessing
only the unbound partner in a mixture of bound and unbound molecules55–58. The KinExA
instrument is an automatic solution-handling system equipped with a sensitive and
versatile fluorescence detection system55,59–61. To perform measurements, a small volume
of a bi-molecular reaction mixture is flowed into a low-volume flow cell over a solid
phase consisting of small beads functionalized to specifically bind one of the
partners52,56,62. The contact time between the beads and solution is brief enough that any
dissociation of the bi-molecular complex is insignificant. The beads specifically capture a
small fraction of the free partner, proportional to total free molecule in solution, which is
quantified by either intrinsic fluorescence of the captured molecules or by using
fluorescent secondary probes (i.e., specific labels, anti-tag, or anti-species secondary
antibody) that do not participate in the primary interaction in the solution phase 63,64.
Depending on the experiment goals, the resulting fluorescence signal measured directly

47
on the beads is analyzed using various binding models and protocols to determine
kinetics, affinity, or concentration48,50,55,58,65–69.
Although this technology has been chiefly used with antibodies as biorecognition
elements46,54–56,70, the only restriction on recognition molecules is that at least one of them
needs to be fluorescently detectable, either directly or indirectly55. We used this
technology to interrogate an aptamer-thrombin binding system, and our protocols make
full use of the advantages offered by the KinExA technology in terms of automation,
accuracy, reliability, and adaptability. In addition, the use of aptamers enables using a
complementary DNA on a solid phase71–74 to specifically capture the free aptamer in
solution (unbound to the target thrombin). By introducing a fluorescently-labeled aptamer
as a specific biorecognition element for thrombin, the detection of the unbound aptamer
can be achieved without using a secondary label. Our results demonstrate that the
KinExA platform is directly applicable to aptamers for determining their affinity for
target, whether simple or complex binding stoichiometries are considered, and for
measuring concentration of target molecules.
2. Materials and Methods
The 29 nucleotide thrombin-specific aptamer (sequence 5′AGTCCGTGGTAGGGCAGGTTGGGGTGACT-3′), identified by Tasset et al.34 was
obtained by custom order from Integrated DNA Technologies, Inc. (IDT, Coralville, IA,
USA). At our request, the supplier provided the aptamer modified at the 5′ end by the
addition of the fluorophore Alexa Fluor 647 to enable direct fluorescent detection. For the
capture DNA (cDNA) strand, we selected a 16-nucleotide sequence complementary to
bases 11–26, with two additional thymine residues and biotin at the 3′ end (5′-
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CACCCCAACCTGCCCTTT-biotin-3′). This material was also obtained by custom order
from IDT. The DNA strands were reconstituted with nuclease-free water to a stock
concentration of 100 µM. Sample solutions consisting of fluorescent aptamer (FA) with
various concentrations of thrombin (MilliporeSigma, St. Louis, MO, USA) being
prepared in sample buffer (SB), consisting of phosphate buffered saline with 0.02%
sodium azide (PBS, Sapidyne Instruments) supplemented with 1 mg/mL bovine serum
albumin (BSA, Sapidyne Instruments). The running buffer consisted of PBS alone.
2.1. Solid Phase and Sample Preparation, and Data Collection with the KinExA 3200
Instrument
The multi-step preparation of functionalized beads as solid phase for capturing the
free FA in solution is shown schematically in Figure 2-1. Following the manufacturer’s
guidance, 1 mL of 20 µg/mL BSA-biotin (MilliporeSigma) in PBS was mixed with 200
mg of polymethylmethacrylate (PMMA) beads of 98 µm average diameter (Sapidyne
Instruments). The beads were rotated for two hours at room temperature, after which we
performed five steps of gravity pelleting/PBS washing. Next, the beads were exposed to
100 µg/mL egg white avidin (MilliporeSigma) in PBS containing 10 mg/mL BSA and
rotated for two hours to functionalize them for anchoring the biotinylated cDNA
molecule through the strong biotin-avidin bond. After five steps of gravity pelleting/PBS
washing, one vial of beads functionalized with BSA-biotin and avidin (BSA-B-A) was
reserved for preliminary control experiments, while another vial underwent a last step of
functionalization by immobilizing the biotinylated cDNA on the beads, following similar
equilibration and washing procedures in which we used as bathing solution 1 mL of 2 µM

49
biotinylated cDNA in PBS. The cDNA functionalized beads (BSA-B-A-cDNA) were
further used for control, equilibrium, and concentration measurement experiments.

Figure 2-1.

Bead preparation for equilibrium and concentration measurements
with the kinetics exclusion assay technology.
Polymethylmethacrylate (PMMA) beads functionalized with bovine serum albumin
(BSA)-biotin and avidin serve as anchoring elements for the DNA strand with
sequence complementary to a portion of the fluorescent aptamer. The free aptamer
is able to bind the complementary strand anchored to the bead, while binding of the
aptamer-thrombin complex is prevented.
For the control experiments, we utilized the BSA-B-A and BSA-B-A-cDNA
functionalized beads, which were automatically injected into the flow cell of the KinExA
3200 instrument with autosampler (Sapidyne Instruments). The controls included samples
consisting of PBS alone (for baseline) or 50 pM FA prepared in SB. The equilibrium
measurements (see Figure A1 and the explanations provided in Appendix A) employed a
constant concentration of FA (i.e., 10 pM, 50 pM, and 10 nM) in SB, mixed with
thrombin at final concentrations up to 1 µM, and equilibrated for at least two hours at
room temperature. To demonstrate the potential of the technology for concentration and
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diagnostic testing using aptamers, we prepared mixtures of FA (50 pM) and thrombin (5
nM, 2.5 nM, and 0.5 nM). These samples were equilibrated at room temperature for two
hours.
Aliquots of samples were passed over the functionalized beads in the flow cell of
the instrument. A fresh aliquot of functionalized beads was used for each sample and
replaced automatically using the default protocol supplied with the instrument. Sample
measurement steps consisted of initiation with a flow of 100 µL of PBS, injection of 1
mL of the analytical sample (or control), and injection of 1 mL of PBS, all at a flow rate
of 0.5 mL/min. This was followed by a final rinse with 1.5 mL of PBS at a rate of 1.5
mL/min. The fluorescence data from the detector (expressed in volts) was recorded at a
rate of one sample/second during the above steps and plotted for data interpretation (see
Figure A1 in Appendix A for reference) and further analysis. The same measurement
steps were followed throughout for concentration measurements.
2.2. Data Analysis
Details of the signal equation used for fitting the 1:1 binding model55,59,75,76, ncurve analysis module54,67,70,76, mixed model75,77, and logistic equation for concentration
determination61,78 are provided in Appendix A. The data were analyzed and plotted with
KinExA Pro software (version 4.4.36, Sapidyne Instruments), and Origin 8.5.1 software
(Origin Labs, Northampton, MA, USA).
3. Results and Discussion
In this work, we investigated the suitability of the kinetic exclusion assay
technology for measuring an aptamer’s binding affinity for its designated target, and for
using the aptamer as a recognition element in a bioassay for thrombin concentration
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measurements. Our proposed investigative platform employs BSA-B-A-cDNA
functionalized beads to capture a fraction of the free FA remaining in equilibrated
mixtures of analyte (thrombin) and FA. A potential impediment to this approach would
be an unexpected strong, non-specific binding of the aptamer molecules to functionalized
beads in the absence of cDNA immobilized on their surface. To address this issue, we
performed preliminary investigations of specific and non-specific binding by employing
functionalized beads without and with cDNA immobilized on their surface (control and
capture beads, respectively) and running the experiments with 1 mL of either FA-free SB
or SB containing 50 pM FA.
The analysis of the evolution of the raw fluorescence signal (Figure 2-2) shows
steady, almost identical baselines (~1 V absolute signal value) recorded for both types of
beads in the absence of FA in the solutions. When the FA sample reached the flow cell
containing control beads, the fluorescence started to slowly increase and reached a
maximum value of ~1.1 V (~0.1 V above baseline). Such a small change of the signal
was expected since the FA concentration in the flow solution was very low (50 pM).
During the rinsing step, the free FA was washed away with the buffer, as inferred from
the gradual decrease of the fluorescence signal. The small difference from the baseline
recorded at the end of the trace versus baseline indicated a weak, non-specific binding
(NSB).
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Figure 2-2. Preliminary testing of the fluorescent aptamer’s suitability for
equilibrium and concentration measurements by kinetic exclusion assay.
The tests investigated specific and non-specific binding of 50 pM fluorescent
aptamer (FA) to control and capture beads. All the data in the graphs represent
experimental values, with the symbols added for identification. Each curve shows
the average values of experimental data (n = 3, ±SD).
When the FA-containing sample was flowed over capture beads (BSA-B-AcDNA), the fluorescence signal increased significantly (Figure 2-2) and reached an
absolute value of ~2.9 V (~1.9 V above baseline). This much larger signal may be
explained by a continuous accumulation of the FA in the flow cell as it was captured by
the cDNA immobilized on the capture beads. The signal decreased by only a small
fraction during the rinsing process, suggesting that the FA bound very strongly to the
capturing beads. This was anticipated since the resulting duplex DNA, although relatively
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short, has a predicted melting temperature of 58.4° C and the estimated free energy for
hybridization is large (∆G = −39 kcal/mole; supplier data).
The specific binding of free FA resulted in a strong increase in the fluorescence
signal (~1.9 V above the baseline), while the non-specific binding led to a change in the
signal of less than 0.1 V. Consequently, we concluded that the experimental system was
adequate for initiating further investigation of affinity and concentration measurements.
Having established the existence of specific FA binding to our functionalized
solid phase, we turned our attention to determining the affinity of the aptamer for
thrombin from kinetic exclusion assay experiments. We assumed that the FA-thrombin
complex will not be able to form a duplex with the cDNA; therefore, specific capture of
the complex will be prevented. In accordance with standard practice for n-curve analysis,
we set up three experimental curves, for which we adjusted the concentration of the FA in
SB (i.e., 10 pM, 50 pM, and 1 nM, respectively), used as a constant binding partner
(CBP) for each curve. The thrombin amount in the sample tubes was adjusted (titrated)
for final concentrations ranging from 5 pM to 1 µM, and we used up to 18 thrombin
concentrations (including no thrombin samples) for the experiments. The 1 nM and 50
pM FA samples were incubated for two hours, and the 10 pM FA samples were incubated
for 6.5 h before measurements with the KinExA 3200 instrument, and each sample set
was run at least in duplicate. A typical run for the sample set that utilized 50 pM FA as
CBP is shown in Figure 2-3. The plot clearly indicates that the fluorescence signal,
indicative of free FA in the equilibrated solutions decreased significantly as the titrant
(thrombin) concentration increased. The slope of the traces increased with the amount of
free FA in the equilibrated samples (therefore, it decreased as more thrombin was added
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to the reaction tubes), and confirmed the signal rate’s dependency on the concentration of
binding partner74.

Figure 2-3. The evolution of the raw fluorescence signal recorded from capturing
the free FA left in solutions equilibrated with various thrombin concentrations.
The free FA availability decreased as the titrant concentration in the samples
increased. For this experiment we utilized 50 pM FA as constant binding partner
(CBP).
The curves corresponding to the three different FA concentrations were
simultaneously analyzed with the n-curve analysis module54,67,70,76 included with the
KinExA Pro software package to determine the equilibrium dissociation constant KD. The
calculated percent of free FA vs. thrombin concentration and the theoretical curves for
the three FA concentrations for a 1:1 binding model (Equation (A1)) are shown in Figure
2-4a.
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Figure 2-4. Analysis of FA binding data.
(a) The n-curve analysis provided the calculated percent free FA (symbols) and
theoretical simulations (dashed lines) for 10 pM, 50 pM, and 1 nM FA in the
thrombin-titrated solutions for a 1:1 binding model. (b) The 10 pM and 1 nM FA
signal data (symbols) were fitted with a binding model (dashed lines) that comprised
a hypothetical mixture of two competing aptamers, characterized by different KD
values. The experimental data represents average values ± SD (n = 3 for 50 pM FA,
and n = 2 for 10 pM and 1 nM FA).
The n-curve analysis provided a KD of 298 pM (+111/−81 pM), which is in good
agreement with previous estimates of the same aptamer-thrombin system of ~0.5 nM34, or
a few nM40,41. We also noted that the 10 pM and 50 pM FA curves were nearly identical
(Figure 2-4a), which can only occur when the thrombin concentration corresponding to
the 50% inhibition point (approximately 300 pM) of both curves is equal to the KD59. In
addition to data overlapping, the 10 pM and 50 pM FA concentrations exhibited a better
fit than the 10 nM FA samples. Even so, one may observe a distinct deviation of the data
from the 1:1 binding model used for analysis (i.e., Equation (A1)) for the higher thrombin
concentrations. All the additional curves we obtained and analyzed showed the same
systematic error in the same range. Aware that mixtures of antibodies can generate
standard binding curves of similar appearance75,77, we wondered if the fit discrepancies in
Figure 2-4a could be the result of competition between two or more populations of FA,
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each with its own affinity for thrombin. To examine this hypothesis, we followed the
example provided by Glass et al.77 and set up a model that accounted for the competition
of two FA of differing KD for thrombin59,75. With this competitive binding model, we
obtained a qualitatively better fit to the measured data (Figure 2-4b), which corresponded
to a hypothetical two component FA mixture, in which 84% has a calculated KD for
thrombin of 298 pM, and the remaining 16% has a KD of 500 nM.
A better fit is not sufficient to prove that the dual binding model is the correct
one, and we have no reason to believe that the mixture, if it exists, would have only two
components. In this regard, we note that the fitted FA activity in Figure 2-4 was only
~47% for all FA concentrations, suggesting that half of the FA was actually inactive with
regard to binding thrombin. Previous investigations on the same aptamer considered
either a 1:1 binding model or models that imply multiple binding sites, including
cooperativity and induced fit mechanisms29,35–41. Nonetheless, almost all of those
approaches report significantly lower affinities, and the possibility of a mixed population
was not addressed. The fluorescent label that we added to the aptamer may alter the
binding and equilibrium, but most of the studies cited herein as comparison have also
used labels or spacers as modifiers. We do not believe that this particular label addition
led to such a significant increase in affinity, although this potential effect is worthy of
further investigations. The complex binding observed in our case may be inherent to this
aptamer, or may originate in a potential duplex formation between a shorter segment of
the cDNA and a complementary sequence of the FA outside the thrombin binding site.
Either way, it is a strength of the KinExA technology that deviation from 1:1 binding can
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be discerned in the collected data, which we anticipate will prompt further inquiry into
mechanisms that may explain the observed binding curves for this and other aptamers.
Our next experiments aimed at evaluating the FA as a bioassay recognition
element using kinetics exclusion assay technology. This task does not require a welldefined KD, only that we have a reproducible standard curve. To measure thrombin
concentration by employing kinetic exclusion assay using aptamers as ligands, we
included measurements of mock unknowns (i.e., 5.0 nM, 2.0 nM, and 0.25 nM thrombin
concentration) in the 50 pM FA assay. Similar to the experimental results plotted in
Figure 2-3, the resulting raw signal curves (Figure 2-5a) recorded with the equilibrated
mock samples show that the end signal decreased substantially when the thrombin
concentration increased, indicating reduced availability of FA in the equilibrated
mixtures.
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Figure 2-5.

Equilibrium measurements of thrombin concentration by kinetic
exclusion assay.
(a) The raw fluorescence signal recorded for thrombin concentrations of 0.25 nM, 2
nM, and 5 nM (n = 3, ± SD) in equilibrated mixtures at a constant FA concentration
of 50 pM. The symbols were added to facilitate curve discrimination and
identification. (b) The end signal values measured against the baseline for standard
and mock samples (symbols) were plotted and fitted (dashed line) with the fourparameter logistic equation (Equation (A2)) to determine the unknowns. The range
of concentrations represented by the x error bars on the “measured” data points
represent concentrations corresponding to the average measured signal (n = 3) ±SD
of the measured signals.
Since the 1:1 binding model (Equation (A1)) proved unsatisfactory to best
describe the experimental data, we used the four-parameter logistic (Hill slope) equation
(Equation (A2))61,78 to fit the signal data for the standard curve (Figure 2-5b). The best fit
parameter values calculated with this model are: upper asymptotic value B1 = 2.0 V,
lower asymptotic plateau (NSB) B2 = 0.38 V, inflection point B3 = 0.32 nM, and a Hill
slope B4 = 0.87. These parameters were also used to compute the “unknown”
concentrations from the average values of the respective signals using Equation (A3).
Our calculations provided average concentration values equal to 5.4 nM for the 5 nM
sample, 2.2 nM for the 2.0 nM sample, and 0.32 nM for the 0.25 nM sample (Figure 2-
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5b). It is interesting that although only one of the samples (i.e., 0.25 nM thrombin) had a
concentration near the middle of the curve, while the more concentrated samples were
intentionally outside this region, the determined average concentration values were
satisfactory. As expected, the uncertainty in the determined concentration is larger and
asymmetrical for the higher concentrations because of the more gradual slope and
curvature of the standard curve at these concentrations. From the signal curve (Figure 25b) one may easily observe that for this FA concentration, visible changes in the binding
signal occurs for thrombin concentrations in the pM range; further optimizations of the
FA concentration in relation to affinity may provide improved sensitivity, even in the
sub-pM range59.
4. Conclusions
This work strongly supports the hypothesis that the kinetic exclusion assay
technology is suitable for kinetics and equilibrium measurements employing aptamers as
specific biorecognition elements. Our experimental results demonstrate that both aptamer
characterization and analyte concentration measurements are achievable through this
methodology. All the advantages presented by this technology are anticipated to be
maintained when aptamers are used as ligands for analytes. The KinExA technology does
not suffer from surface matrix affinity effects45,79, mass transport limitations, or mobility
effects55,80, does not require radioactive labels, avoids any surface-immobilization
procedure that may alter binding constants compared to those measured in true solution
phase, is highly accurate for repeated readings81, and has no molecular weight limitations
55,82,83

. Multiple studies have revealed its superiority to SPR or ELISA in terms of

accuracy, sensitivity, versatility, and reliability45,48,49,76,81,82,84. The instrument may assess,
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in various formats, the binding of partners ranging from ions82,83 and small
molecules50,85,86 to large structures (e.g., whole cells, including fixed cells)49,76,85,87, which
makes aptamers an excellent choice for numerous kinetics, equilibrium, and
concentration measurements by using the KinExA technology. The ability to identify
complex binding stoichiometries may provide valuable insights into fundamental
analyses of aptamer–analyte interactions, while its high sensitivity and accuracy
recommend this technique for numerous bioanalytical applications.
Appendix A
Kinetics Exclusion Assay Principles
The principles of measurement and the anticipated evolution of the fluorescence
signals during the various steps of the adapted protocol are briefly presented in Figure
A1. The instrument automatically handles the packing of beads and the injection of all
the required solutions into the microfluidic system, while monitoring the fluorescence
signal of the label captured by the beads. In our case, the beads (Figure A1, panel A) are
functionalized for capturing the free FA by following the procedures presented in
Materials and Methods and Figure 2-1, and introduced into the flow cell. The reactants
(FA and thrombin) are equilibrated in reaction tubes in which we kept constant the
concentration of FA and varied the amount of thrombin (Figure A1, panel B). The
concentration of free FA in pre-equilibrated solutions is in inverse proportion to the
amount of thrombin added to the reaction tube. A fraction of the free FA is captured by
the functionalized beads upon injection into the flow cell (Figure A1, panel C). For
otherwise identical settings, the amount of captured FA is proportional to the amount of
free FA; more thrombin in the equilibrated sample leads to less FA available for capture.
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FA injection after bead handling leads to an immediate increase in fluorescence signal
owing to specific capture on the beads (Figure A1, panel D). The subsequent rinsing step
washes away any non-captured FA, with the end signal representing only captured FA.
This end signal is proportional to the amount of free FA that was injected in the previous
step. It is assumed that the FA-thrombin complex (bound FA) will not bind to the cDNA,
and the rate of dissociation of the pre-equilibrated complex is slow enough to be
negligible during the brief residence time in the flow cell. Consequently, the end signal
represents only binding of a fraction of FA free in equilibrated FA-thrombin solutions.
An affinity value may be derived from further analysis of the relative changes in the end
signal versus baseline (Figure A1, panel D) of a series of equilibrated solutions55,59.
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Figure A1.

Using aptamers as biorecognition elements for kinetic exclusion assay
measurements.
(A) A pack of beads functionalized with cDNA for FA capture is introduced in the
flow cell. (B) Samples consisting of constant FA concentrations and variable
thrombin amounts are equilibrated in test tubes. (C) Aliquots of equilibrated
samples are flowed over the beads in the flow cell and a fraction of free FA is
captured. This fraction is inversely proportional to the amount of thrombin added
during the equilibration step. (D) The expected evolution of the fluorescence signal
in response to different concentrations of free FA in solution. FA injection produces
an increasing fluorescence signal owing to its capture and accumulation onto beads.
The end signal recorded after the unbound FA is rinsed from the flow cell is
proportional to the amount of free FA present in the equilibrated sample (not
complexed with thrombin). For identical label (FA) concentrations in equilibrated
solutions, the end signal decreases as the concentration of the target molecule
(thrombin) increases, indicative of a reduced availability of the free, unbound label.
Signal Equations and Modeling
The instrument end signal as a function of concentration for a 1:1 binding model
is described by Equation (A1)55,59,75,76:
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(𝐴𝐴1)

where Sig100% represents the end signal recorded in the absence of thrombin in the

mixture, NSB is the end signal corresponding to non-specific binding (or the signal when
all of the aptamer is complexed with thrombin), and [FA]0 and [T]0 are the initial
concentrations of FA and thrombin in the mixtures. This equation is fitted by the method
of least squares to the experimental data obtained by using FA as CPB and thrombin as
titrant. The n-curve analysis simultaneously fits Equation (A1) to multiple signal curves
generated by using different CBP concentrations54,67,70,76.
For the two-population aptamer mixture, the total concentration of FA, [FA]0, is
assumed to be composed of two fractions [FA]1 = f × [FA]0, and [FA]2 = (1 − f) × [FA]0,
where f is the fraction of the tightest binder in the population. We assumed that an FA
molecule will provide the same signal irrespective of the population to which it belongs.
For this fit, we used the 298 pM reported in the KinExA n-curve analysis as the tighter
KD, and varied both the fraction f of the tightest binder and the KD of the second fraction.
The competitive equilibrium concentrations of FA1 and FA2 were calculated using a
model described elsewhere75,77. We scaled the resulting combined free fraction of FA
using a maximum binding signal (Sig100%) and offset it using a non-specific binding
variable (NSB), as has been reported previously59,75.
For the mock sample concentration measurement, the standard binding curve was
obtained by averaging and fitting with a four-parameter logistic equation61,78:
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where B1 is the upper asymptotic plateau (maximum signal), B2 is the lower
asymptotic plateau (NSB), B3 is the inflection point (the concentration at which the signal
is halfway between the extreme values), B4 is the Hill coefficient (slope), and x is the
titrant’s concentration.
The same equation, rearranged to solve for x, allows calculation of the unknown
concentrations from the corresponding signals:
−(−𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 + 𝐵𝐵1 )
𝑙𝑙𝑙𝑙 � (
�
−𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 + 𝐵𝐵2 )
[𝑥𝑥 ] = 𝑒𝑒𝑒𝑒𝑒𝑒 �
� ⋅ 𝐵𝐵3
𝐵𝐵4

(𝐴𝐴3)
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CHAPTER THREE: AFFINITY MEASUREMENTS OF LIGANDS TO
IMMOBILIZED NATURAL AND ARTIFICIAL MEMBRANES BY KINETIC
EXCLUSION ASSAY
Introduction
The cellular membrane, with its myriad inclusions, provides a communication
channel as well as a boundary and barrier between the cell and its surroundings. Both the
barrier function and communication are essential to the health or disease for all of life 1.
The two major membrane components, i.e. lipids and proteins, create and maintain
electrochemical gradients; transport nutrients and wastes; and monitor the extracellular
environment and facilitate the cell’s response to nutrients, toxins, signaling molecules,
adjacent cells and surfaces, and other exogenous stimuli1–4. These numerous and complex
functionalities rely on primary, specific interactions between ligands of various types and
components of cell membranes. The characterization of these interactions is of utmost
importance for a large variety of scientific, biotechnological, and biomedical
applications.
Membrane components constitute preferred targets for more than 60% of drugs
currently on the market5–8. Therapeutic antibodies target membrane proteins to treat
cancer, inflammatory and autoimmune diseases9–13. Viruses must breach the cell
membrane barrier to enter the cell, and many bacterial toxins manifest their mischief by
disrupting the integrity of the cell membrane14–21. The development of any
chemotherapeutic strategy aimed at hindering or potentiating these processes at the
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membrane level must incorporate a quantitative measurement of those interactions.
Specific components of cell membranes are also of great scientific interest for
applications such as imaging, manipulation of cellular functions, or to better understand
the complex membrane environment22–29. Therefore, understanding vital cellular
functions and screening for new drug targets and more potent therapeutics requires
affinity measurements to these membrane components.
Quantification of membrane-ligand interactions poses particular challenges to
both experimental design and theoretical modeling22,23,25,30–33. Cell membranes are unique
mixtures of lipids and proteins, self-assembled into a dynamic matrix described as a fluid
mosaic1. The affinity of membrane components with their ligands can be influenced by
the particular chemical composition of the membrane, mutual lipid-protein interactions,
physical state (i.e., particular thermodynamic phase), internal organization into domains,
or membrane curvature16,18,20,23,34–40. Isolated from this intricate structure, lipids and
membrane proteins may interact very differently or not at all with their ligands. These
considerations argue for measuring affinities of target molecules presented in a functional
membrane.
A number of analytical techniques, including radioimmunoassay (RIA)41,
enzyme-linked immunosorbent assay (ELISA)42,43, surface plasmon resonance
(SPR)20,31,37, electron spin resonance (ESR)31,44, optical spectroscopy2,17,20,28,31,33, and
imaging assays28,29,31,33,45, have been applied to describe interactions with biological
membranes both qualitatively and quantitatively. Current methodologies generally
measure the interaction between one soluble reactant and the other immobilized on a
solid surface46. The immobilization of one component may introduce surface matrix
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artifacts to the measurement47,48, or may present an unsatisfactory orientation of the
molecule49,50. Dedicated techniques have been recently developed to quantify binding at
membrane interfaces but their utility was demonstrated only for particular experimental
systems15,51. In addition, these experimental explorations are accompanied by a large
variety of theoretical and computational approaches unique to the experimental
conditions5,23,25,30,32. Among these techniques, the kinetic exclusion assay (KinExA)
presents an appealing choice for assessing membrane-ligand interactions in various
experimental formats9–12,52.
The KinExA technology measures the free amount of a binding partner left in an
equilibrated solution that contains a specified amount of one partner (constant binding
partner, CBP) and a variable amount of the other (titrant, T). The first step involves
equilibration of the binding partners in solution, therefore closely resembling
physiological conditions, and does not require any labeling or immobilization that may
obscure the true binding constants. As the initial concentration of titrant increases, the
equilibrium concentration of free CPB will decrease. The equilibrated solution is then
flowed over a bead pack in a small flow cell, functionalized to specifically bind the CBP
molecules. A portion of the free CBP is captured on the beads, and the captured fraction
is quantified by fluorescence provided either from the captured molecules themselves or
by secondary labels. The fluorescence signal is analyzed by fitting the experimental data
to a binding model that provides exact analytical solutions to accurately determine
affinity. This technology has been employed to accurately measure affinities of
antibodies for cell surface receptors by using live cells as binding partners9,11. The use of
live cells may introduce uncontrolled irregularities such as batch variability, artifacts
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presented by persistent growth of cells during equilibration and measurements, or
secretion of compounds or even a physiological response that may interfere with the
interactions under scrutiny. To alleviate some of these problems, a “lifeless” membrane
system made from ruptured membranes was recently used for binding affinity
determination of therapeutic antibodies to membrane targets12. However, this
methodology required multiple isolation and purification steps to eliminate potential
artifacts arising from a low purity of the analyzed membranes.
In this work we use artificial and natural membranes as capture elements to
extend KinExA technology into this realm. KinExA-based measurements generally use
immobilized binding partners or antibodies as capture elements9,10,12, which are not
always available for the intended measurements. A common approach to preparing these
capture elements is to first coat polymethylmethacrylate (PMMA) beads (among other
materials) with biotinylated bovine serum albumin (btn-BSA), followed by attachment of
a biotinylated molecule through an avidin sandwich process. Previous reports have
documented the use of cholesterol-based anchor lipids to modify the surface properties of
cells and lipids53 and to anchor cells to solid surfaces54. With this knowledge, it was
reasonable to suppose that this linker could be used to anchor liposomes, made from both
natural and artificial membranes, to the beads used in the KinExA process.
Using the improved approach described in this work, the natural receptor of the
ligand we are measuring is also the capture element. We tested this experimental system
to quantify the interactions between lipophilic dyes and artificial liposomes, cholera toxin
subunit B (CTB) and artificial liposomes containing gangliosides, and sheep red blood
cells and their antibodies. Our results demonstrate that this technology may be used to
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precisely determine affinities for biological membranes of large and small molecules
while eliminating many of the shortcomings plaguing alternative approaches.
Materials and Methods:
Materials:
The lipids asolectin (Aso) and cholesterol (Chol) were purchased from SigmaAldrich, and ovine brain ganglioside (GM1) from Avanti Polar Lipids as powders (Figure
3-1). Stock solutions from the powders were prepared by dissolving the lipids in
chloroform at concentrations up to 100 mg/mL.

Figure 3-1. Lipids used in this study.
Top: Asolectin is a mixture of phosphatidylcholine (shown), cephalin, phosphatidylinositol and a few other minor components, extracted from soy beans; phosphatidylcholine is the major component. Center: Cholesterol. Bottom: Ganglioside GM1.
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The stock solutions were kept frozen until use, and any further dilution was made
with chloroform. Whole sheep blood in Alsevers solution (1:1) was purchased from
Colorado Serum Company (Denver, CO, USA) and kept refrigerated until used to prepare
liposomes from red blood cells (RBCs). A 3 mg/mL stock solution of anti-sheep RBC
antibodies labeled with fluorescein isothiocyanate (FITC) was purchased from LifeSpan
Biosciences. CTB labeled with Alexa Fluor 647 (CTB-AF647) from LifeTechnologies
was used for determining the interactions with liposomes. The cholesterol-polyethylene
glycol 2000-biotin linker (Chol-PEG-Btn, Figure 3-2) was purchased from NanoSoft
Polymers, and a stock solution of 1 mg/mL in phosphate buffered saline (PBS) was
prepared and kept frozen until further use.

Figure 3-2.

Chol-PEG-Btn. Cholesterol (left side) is linked to biotin (right side)
through a polyethyleneglycol (PEG2000) linker (middle).

The far red-fluorescing lipophilic carbocyanine dye DiD (1,1'-dioctadecyl3,3,3',3'-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (Figure 3-3), was
purchased from ThermoFisher Scientific as a crystalline salt and was dissolved in pure
ethanol; any further dilution of the stock solution for kinetic exclusion assay
measurements was performed in PBS.
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Figure 3-3. The lipophilic dye, 1,1'-dioctadecyl-3,3,3',3'tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD)
Dry polymethylmethacrylate (PMMA) beads of 75 µm average diameter
(Sapidyne Instruments), functionalized as described below, were used as the solid phase
bead pack for measurements with the KinExA 3200 instrument with autosampler
(Sapidyne Instruments).
Preparation of Liposomes from Lipids
Liposomes, an excellent biomimetic system for characterization of ligandmembrane interactions16,28,31 were prepared from lipids by extrusion28 through filters
mounted in an Avanti lipids extruder. Powdered lipids (Aso, Chol, and GM1) were
dissolved in chloroform, mixed and dried overnight under vacuum in 20 mL glass vials.
The dry weight ratio of the lipids was Aso:Chol:GM1=10:4:0.6. A control preparation
contained the same proportion of Aso to Chol, but with no GM1. The total amount of Aso
added to each vial was 10 mg. After chloroform evaporation, the dried lipid cake was
hydrated for one hour at 55° C in 1.1 mL of a 135 mM KCl solution buffered at neutral
pH with 20 mM HEPES. The hydrated lipid cake was subjected to five cycles of
freezing-thawing, followed by 30 seconds of sonication in a sonicator bath (Fisher
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Scientific) to achieve complete dispersion of the lipid aggregates. The hydrated mixture
was introduced into the extruder equipped with 200 nm polycarbonate filters, and
extruded at low speed for a total of 40 cycles. After extrusion, the liposomes were
assessed by dynamic light scattering (DLS) with a Malvern Zeta-Sizer and found to have
an average diameter of 146.3 nM with a polydispersity index (PDI) value ranging from
0.172 to 0.227 (Figure 3-4); the liposomes were kept refrigerated until further use.

Figure 3-4. Dynamic light scattering characterization of artificial liposomes.
Representative analysis by Malvern Zeta-sizer. The liposomes were prepared by
extrusion.
Preparation of Liposomes from Red Blood Cells
RBCs were separated by centrifugation of 5 mL whole sheep blood in heparinized
tubes at 1500 RCF. The RBC pellet was washed with 5 mL ice-cold PBS. After two more
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cycles of centrifugation-PBS rinsing, the pellet was resuspended in 5 ml of DI water and
refrigerated at 4° C for 1 hour to lyse the cells. After addition of 5 mL PBS, the RBC
cellular membranes (ghosts) were separated in five consecutive cycles of centrifugation
at 18,000 RCF for 5 minutes at 4° C and rinsed with 5 mL PBS. A final volume of 2 mL
RBCs in a glass vial was sonicated with a Misonix S-4000 tip sonicator. The glass vial
was placed on ice, and the sonication was performed for 15 minutes at 25% amplitude
setting, a power transfer of 6-7 W, and a total energy transfer of 5.4 kJ. The liposomes
were sized by DLS in triplicate, which indicated a mean diameter of 144.7 nm and a PDI
ranging from 0.161 to 0.182 (Figure 3-5).

Figure 3-5.

Dynamic light scattering characterization of liposomes made from
RBC.
The liposomes were prepared by extrusion of purified RBC ghosts as described in
the text.

83
Bead Preparation
The procedure for attaching liposomes to beads for kinetic exclusion assay
measurements is depicted in Figure 3-6. Two hundred mg of PMMA beads were mixed
in a vial with 1 mL PBS containing 30 µg biotin-BSA (SigmaAldrich) for adsorption
coating. After rotating the vial for two hours, the beads were washed five times with 1
mL PBS after gravity pelleting. Next, a coating of streptavidin was achieved by mixing
the bead pack with 1 mL PBS containing 100 µg SA and 10 mg BSA, and rotating the
vial for two hours at room temperature55. The free proteins were removed with five
cycles of pelleting/PBS washing. The next step of functionalization consisted of coupling
the Chol-PEG-Btn linker to the surface of the beads via the strong biotin-streptavidin
bonds; this was achieved by mixing the beads with 10 µM Chol-PEG-Btn linker in 1 mL
PBS, and rotating the vial for three hours at room temperature. After five cycles of
pelleting/PBS washing, the final step of bead preparation was liposome attachment. To
anchor the liposomes to the beads, the bead pack was mixed with either 400 µL of
extruded liposomes or 800 µL of RBC liposomes and rotated overnight in a refrigerator.
After removal of free liposomes by pelleting/PBS washing, the beads were placed in a
bead vial for the KinExA 3200 instrument, and PBS added for a total volume of 30 mL.
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Figure 3.6. Schematic representation of liposome attachment to PMMA beads.
PMMA beads were coated with biotin-conjugated BSA by adsorption. Streptavidin
was added to activate the surface, and the surface was further functionalized by the
addition of Chol-PEG-Btn. The cholesterol moiety self-inserts into membranes to
capture the liposomes.
The functionalized beads were used as the ligand-capturing solid state phase for
kinetics exclusion assays of the affinity of toxins. All of the ligands used were
fluorescent, either intrinsically or by labeling. For this investigation, we employed CTBAF647, fluorescein-labeled anti-sheep RBC antibodies, and the lipophilic dye DiD,
prepared as described in the materials section.
Results and Discussions
Measuring the Interactions Between Gangliosides and CTB-AF647.
To determine the affinity of CTB for GM1, we used beads functionalized with
GM1 liposomes to capture the free CTB-AF647 from solutions pre-equilibrated with
liposomes. Two mL aliquots of a 10 pM CTB-AF647 solution as the constant binding
partner were mixed with varying amounts of liposomes (thus different concentrations of
GM1) as titrant. The GM1 concentration in the sample vials varied from 0.1 nM to 200
nM. The solutions were equilibrated for 6 hours at 25° C and introduced for automatic
measurements in the autosampler of the KinExA 3200 instrument. It is notable that we
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did not perform any additional separation of the free CTB-AF from solutions; we
assumed that the CTB-AF647 bound to liposomes would not interact with the liposomes
anchored to the PMMA beads, and only the free toxin would bind to the liposomes on the
beads. Also, due to the small size of the liposomes (~200 nm), we assumed that all the
liposomes free in solution would pass through the flow cell during the process. This is a
very reasonable assumption since the mesh size of the filter that keeps the beads in the
flow cell is ~20 µm, which is ~100 times larger than the average size of the liposomes.
After equilibration, the evolution of the fluorescence signal for each sample was
measured with the KinExA instrument. For GM1 liposomes, the fluorescence of CTBAF647 started to increase monotonically immediately when the bolus reached the flow
cell (Figure 3-7). The increasing signal represents the fluorescence recorded from both
free and bound CTB-AF647 (either to liposomes in the equilibrated solutions, or
liposomes anchored to the beads). The buffer exchange removes the free ligand and the
ligand bound to liposomes in solution, which is seen as a decrease of the fluorescence
signal. The end signal is given by the fraction of CTB-AF647 attached to the beads, and
is proportional to the amount of free ligand in solution. One may easily observe that
increased amounts of GM1 liposomes in the equilibrated solutions resulted in a decreased
end signal, indicating a smaller amount of free CTB-AF647.
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Figure 3-7. KinExA sensogram of CTB captured by GM1 liposomes.
Ten pM CTB was mixed with varying amounts of liposomes (thus of GM1) and
allowed to equilibrate. The equilibrated solution was analyzed by KinExA with
liposomes immobilized on PMMA beads as the capture element.
The end signal was plotted as percent maximum versus GM1 concentration and
the KinExAPro software provided a KD value of 5.98 nM ± 0.78% for the GM1-CTB
interaction (Figure 3-8). This value is well within the range reported for such interactions
by employing alternative techniques16,20,37,38. However, this value must be carefully
interpreted for its meaning with respect to molecular interactions. The interaction
between the CTB ligand and GM1 is not at all a traditional bimolecular interaction since
GM1 is actually included in a membrane. It is not known how the physical and chemical
properties of the membrane (i.e., composition, curvature, lipid segregation) affect the
interaction. The interactions between membrane and ligands might be better described as
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a Langmuir absorption process, and the affinity estimated as either a Langmuir constant
or partition coefficient.
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Figure 3-8. Theory curve for CTB binding to GM1 liposomes.
Data shown in Figure 3-7 was analyzed by KinExAPro software to generate a KD
estimate of 5.98 nM ± 0.78%.
Next, we asked whether or not GM1 is an essential receptor for CTB interactions
with membranes16,20,37,38. To answer this question, we prepared the beads by following
the same protocol previously described but used liposomes containing no GM1 lipids.
The testing was initiated by flowing only CTB-AF647 over the liposome-functionalized
beads. To get an idea of the magnitude of the interactions, we increased the CTB-AF647
100 fold (i.e., 1.0 nM). At this very high ligand concentration, the fluorescence signal
increased monotonically during injection and reached a very large value (10 V, Figure 3-
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9). Nonetheless, despite this large fluorescence value, the end signal recorded after
injecting ligand-free buffer in the flow cell decreased to a negligible value. This very
small fluorescence signal, together with the large ligand concentration used in this
experiment, indicates that GM1 is an essential component for interactions between CTB
and membrane, and for the complete cholera toxin to manifest its effects16,20,37,38.
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Figure 3-9. Cholera toxin is not captured by non-GM1 liposomes.
A bed of beads coated with liposomes devoid of GM1 was challenged with a 1.0 nM
solution of CTB-AF647. The immediate decrease in fluorescent signal to a negligible
value upon initiation of the rinse phase shows that very little CTB-AF647 is bound
to the liposome capture element.
The fit of experimental data provided a satisfactory value for affinity, but this was
calculated by employing a single-step, one-to-one binding model. Although this model is
presented in multiple reports, investigators also considered that CTB binding is a multi-
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step, cooperative process35,36,56, with a Hill coefficient less than 2. Therefore, we
employed the logistic equation to calculate the affinity and cooperativity coefficient
(Figure 3-10), which provided a better fit of experimental data (Figure 3-10); the affinity
value (KD = 11.36 ± 0.6 nM) and Hill coefficient (n = 1.36 ± 0.15) are in reasonable
agreement with values reported using other techniques35,38.
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Figure 3-10. Logistic fit of data for CTB captured by GM1 liposomes.
Data shown in Figure 3-7 was analyzed with Origin 8.5 software using a logistical
model to generate a KD estimate of 11.36 ± 0.6 nM, with a Hill coefficient of 1.36 ±
0.15.
Interactions Between Antibodies and Membranes
To investigate the interactions between antibodies and membranes, we assessed
the binding of anti-sheep RBC antibodies to RBCs by employing KinExA. To achieve
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this goal, we used PMMA beads functionalized with RBC liposomes as described in
Methods. However, the specific target of the antibodies on the membrane surface is
unknown, and no quantitative indication of affinity or titer was provided by the supplier.
To characterize the antibodies, we attempted fluorescence microscopy imaging; while
this approach allowed us to verify specific staining, sustained photobleaching even during
short exposure precluded any quantitative analysis. In addition, we were able to surmise
that the antibodies do not possess a great affinity for the target since the fluorescent
images faded significantly after washing, or by antibody dilution with buffered isotonic
solutions added to the bulk.
The great advantage of the KinExA technology is that it requires knowing the
concentration of only one partner participating at the binding reaction in the equilibrated
samples, and this is essential for assessing membrane-ligand interactions in which only
one partner (usually the ligand) has a known concentration. In our analysis, we used the
RBC liposome beads to capture the free Ab from solution, while the equilibrated samples
comprised a fixed concentration of Ab (100 nM) and a variable number of RBCs.
Although the RBC liposomes may be also used as titrant, a more thorough analysis
requires knowing the number of liposomes/sample. Owing to their small size, they cannot
be easily quantified. A rough estimate of their concentration may be obtained from lipid
concentration and average size; nonetheless, one may encounter major deviations
between theoretical estimates and experimental values owing to loss of lipids during
preparation procedures, polydispersity, addition of small molecules (i.e., cholesterol), and
many other factors. In contrast, cellular densities may be accurately determined by
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cytometry. Therefore, we used RBCs as titrant to generate the Ab-RBC equilibrated
samples for KinExA measurements after 3 hours of equilibration at 25° C.
The equilibrated samples were introduced into the fluidic system of the KinExA
3200 instrument equipped with a set of fluorescein filters. The end signal for each run
increased as the concentration of the titrant (RBC) decreased, resulting in more free Ab
available to interact with the RBC liposomes anchored to the beads (Figure 3-11).

Figure 3-11. KinExA sensogram for anti-RBC antibodies equilibrated to RBCs.
Constant concentrations of Ab were equilibrated against varying amounts of RBCs.
The equilibrated solutions were analyzed by KinExA with PMMA beads
functionalized with liposomes made from RBCs as capture element.
The binding signal expressed in percent maximum was fitted with the binding
equation, accounting for the number of cells present in each sample (Figure 3-12). Data
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analysis with KinExAPro software provided an affinity value KD = 38.6 nM ± 0.2%. The
antibodies we used are polyclonal, and thus represent multiple molecular targets on the
surface of the RBCs. As a result, the number of binding sites/cell reflects the cumulative
number of targets present on cell membranes, irrespective of their chemical identity.
Thus, this KD value certainly needs to be interpreted as Ab affinity for the entire RBC
membrane instead of a specific receptor. Despite this apparent shortcoming, there is no
doubt that the affinity value is not high, which we anticipated from microscopy imaging
experiments. However, since we were able to provide the number of cells as an input
parameter, the software can estimate the “expression level” (site density) to be 4.7 x 106
binding sites/cell. Consequently, this technique can also be very useful in determining the
expression level for known targets on the surface of cells with monoclonal antibodies.
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Figure 3-12. Theory curve for anti-RBC Ab and RBC liposomes.
The sensogram data shown in Figure 3-11 were analyzed by KinExAPro software to
return a binding KD of 38.6 nM ± 0.2%, and an antigen expression level of 4.7 x 106
binding sites per cell.
Determining the Affinity of Lipophilic Dyes for Lipid Membranes
Lipophilic dyes are molecular tools largely used for membrane imaging and
tracing in live cells and artificial membrane systems26–29,57,58. They are well characterized
for their optical properties (i.e., fluorescence characteristics), and also their mechanisms
of interactions with target membranes and how such interactions change their
fluorescence27–29, but their use is not standardized, nor is it clear which one should be
used for a particular experiment. All lipophilic dyes, as their name indicates, present a
preferential interaction with the lipid portion of cell membranes. As a result of such
interactions, many of them undergo a massive hyperchromic effect (increase of
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fluorescence), or a spectral shift, in a lipophilic environment, therefore facilitating
detection with spectroscopy or microscopy27,28. However, it is not clear how the affinity
changes when the target membrane has a different chemical composition from the test
membrane. Consequently, a rapid method for measuring the affinity of lipophilic dyes for
target membranes may provide a useful means of determining the applicability of such
dyes for particular applications. To explore this possibility, we employed KinExA to
determine the affinity of the lipophilic dye DiD for artificial membrane systems.
The PMMA beads were functionalized with liposomes composed of Aso and
Chol and prepared by extrusion as described in the Methods section. The liposomes were
also used as titrant to prepare equilibrated solutions that contained variable amounts of
liposomes and a constant concentration of lipophilic dye (10 pM). After two hours of
equilibration at room temperature, the samples were centrifuged at 56,000 RCF and the
supernatant assessed for the free dye content by using KinExA and the liposomefunctionalized beads as the capturing solid phase. The evolution of the fluorescence
signal upon sample introduction in the flow cell and subsequent rinse with dye-free
buffer solutions is shown in Figure 3-13. The fluorescence signal starts increasing
immediately as the sample bolus reaches the flow cell, similar to the previous
experiments. This signal is generated by free lipophilic dye molecules interacting with
the membranes of the liposomes attached to the beads. Unlike previous experiments,
rinsing of the bead pack with dye-free buffer does not elicit a visible decrease of the
fluorescence signal. This particular shape is explained by the intrinsic properties of the
label. In a hydrophilic environment, this lipophilic dye presents a weak fluorescence.
However, when inserted into the hydrophobic core of the lipid membranes the intrinsic
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fluorescence increases substantially, hence facilitating its detection. Since the free dye
has a weak fluorescence, its contribution to the total signal is negligible, thus its removal
from the flow cell does not affect the fluorescence signal. Dye molecules bound to
liposomes in the equilibrated samples were removed by centrifugation and, therefore, did
not contribute to the fluorescence signal during analysis. The detected signal is chiefly
generated by the free dye binding to the liposomes attached to the beads. The flat signal
plot recorded during rinsing indicates that the lipophilic dye molecules bind tightly to the
target membranes and do not leave them easily. Similar signal shapes are common when
the fluorescence of the captured molecule far exceeds the fluorescence of the sample
itself59.
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Figure 3-13. KinExA sensogram of DiD equilibrated to liposomes.
Varying amounts of liposomes, reported as lipid concentration, were brought to
equilibrium with a constant concentration of DiD. The liposomes and solution were
separated by centrifugation, and the residual dye analyzed by KinExA.
The binding curve representing the percent signal as function of label
concentration is depicted in Figure 3-14. The best fit performed with the KinExAPro
software provided a KD value of 215 pM ± 0.59%, confirming our prediction with regards
to a high affinity of this particular dye for lipid membranes. To calculate this KD value,
we used the total lipid concentration employed to produce the liposomes. However, as
previously discussed, this analysis is descriptive of molecular absorption at a surface, but
this value may better be interpreted as a partition coefficient. However, unlike a classical
Langmuir isothermal absorption process, although the ligands may interact at first with
only one side of the membrane, they are expected to diffuse into the lipid core of the
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membrane, therefore introducing computational complications when utilizing a
traditional binding model.
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Figure 3-14. Theory curve of dye accumulation by liposomes.
Data shown in Figure 3-13 were analyzed by KinExAPro software, which returned
an apparent KD of 215 pM ± 0.59%.
The KinExA technology, when used with liposome capture elements, provides an
ideal platform for characterizing membrane-ligand interactions with membranepenetrating toxins or lipophilic dyes, as well as with surface-anchoring molecules.
Although the common feature of this and other experimental platforms is the use of
membrane systems anchored to the solid phase to capture the free ligand, the KinExA
approach is unique in pre-equilibrating the receptor-ligand pair in solution with either
cells or biomimetic systems. Nonetheless, one must ponder the interpretation of the KD
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value with respect to molecular interactions, in spite of its extensive use for quantification
of membrane-ligand interactions. Interactions with intact membranes have resisted
measurement by traditional methods. As we previously stated, the ligands may bind
completely differently to the individual target molecules (i.e., lipids, or proteins) when
presented as part of an intact membrane than when presented as a free molecule. Having
one member of the reaction pair anchored into a relatively large and immobile membrane
changes the dimensionality of the system from a tri-dimension to a two-dimension
interaction space4,36,51. This may have consequences on the accuracy of the interaction
model4, which might be better described as a Langmuir absorption process20,38 The
influence of membrane composition, curvature, clustering, cooperative binding, and
target multivalency35–38,40,51,56,60 suggests that avidity or partitioning coefficients may be
more appropriate parameters to characterize ligand-membrane interactions.
Conclusions
KinExA is a powerful platform used to characterize intermolecular binding,
limited only by the ability to capture ligands in the analytical chamber for analysis.
Heretofore, this limitation has been most critical in capturing ligands to transmembrane
proteins or for surface proteins for which a soluble fragment is unavailable. In this work,
we show that:
1) Liposomes produced from natural or artificial membranes can be easily
immobilized in a straightforward manner to the beads used in the KinExA flow cell for
use as capture elements.
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2) Liposomes so immobilized will successfully capture ligands of interest,
whether they be target-specific molecules (e.g., antibodies or toxins) or generalized
molecules (e.g., dyes).
3) Kinetic parameters of academic and commercial interest can be determined
using the liposome immobilization process coupled with KinExA analysis.
Further investigation as to the nature of surface antigens so presented is
warranted. Affinity of surface antigens and their ligands is often measured using soluble
fragments of the former as surrogates, but these surrogates may misrepresent the native
conformation and the resulting measurements may be misleading. Factors such as
oligomerization61, stability62, and function63 may be essential to the interaction and may
be absent from purified fragments. Some efforts to overcome these obstacles have
included detergent micelle preparations63–65 to mimic the trans-membrane milieux, and
formaldehyde fixation10 to preserve native configurations over time. Binding studies of
mAbs to formaldehyde-preserved surface antigens retained full activity for some
antigens, complete inactivation of others, and some in between10. Thus, it can be said that
results were mixed. Micellar purification is wrought with numerous confounding
parameters, often requiring tedious trial-and-error approaches before finding a
satisfactory solution64. Such purified components, nonetheless, may still not mimic native
configurations as other membrane components, lost during purification, may have
significant influence on structure and function.
Our studies presented here promise to extend the use of KinExA analyses to
unpurified and even unknown cell surface reactants, together with determining the
density of the binding sites present on particular membrane systems.
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CHAPTER FOUR: CONCLUSIONS AND PERSPECTIVES
The KinExA concept, and the instrument designed to exploit it, is a sensitive and
versatile method to measure affinity and kinetic data for bimolecular interactions. In the
work represented in this dissertation, I have extended the use of KinExA to encompass
aptamers as both recognition and capture elements, and also described a means of
potentially measuring complex membrane components in a natural setting.
Aptamer Studies
Our experimental results with aptamers demonstrate the utility of using aptamers
as capture elements for analytes of interest, and that KinExA can also be used to
characterize the aptamers themselves. Certain assumptions were made, and realized, in
the design of the experiments presented in Chapter Two and published in the journal
Sensors in 20201. Follow-on work should acknowledge these features, build upon them,
and perhaps circumvent any limitations they might impose.
The first, and most important, assumption was that the thrombin-specific aptamer
would not bind to its complimentary sequence, the capture aptamer, when bound to the
target molecule thrombin. The second assumption was that the free (and only the free)
aptamer would bind to the capture aptamer with sufficient affinity to serve as a
fluorescent beacon. These two assumptions were by no means assured when we began
the study.
In this context, it is worth mentioning that the first thrombin aptamer I
investigated was one identified by Bock et al. in 19922. They identified a 15 nucleotide
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consensus sequence of several aptamers they isolated as GGTTGGTGTGGTTGG.
However, we tested a biotinylated sequence complementary only to a seven nucleotide
sequence on the fluorescent aptamer. Although binding competition was observed, a
relatively fast washing away during the rinse phase was also observed, most probably due
to a fast koff. These results clearly exhibit the “KinExA mode” limitation of the
technology (see Chapter One).
This earlier experience, as well as the published results, suggest a number of
studies to further investigate the system.
1. The Bock and Tasset thrombin aptamers both include a consensus sequence
first identified by Bock. The capture aptamer that we used for the Tasset aptamer has a
complementarity of nine nucleotides, although discontiguous, as opposed to the seven
contiguous nucleotides for the errant capture aptamer. It would be interesting to see if the
Bock aptamer is bound to this capture aptamer, and if so, to compare the affinity.
2. Similarly, what is the minimum complementarity required to efficiently capture
the labeled aptamer?
3. The decreasing signal of captured free aptamer from solution in equilibrium
with its target represents a competitive binding situation. Can this phenomenon be
exploited to identify the key nucleotides of the aptamer binding site? If so, then targeted
chemical modification of those nucleotides could result in even greater affinity and/or
specificity.
4. Can this process be used to identify drugs that will bind to specific sequences
of DNA or RNA and block transcription and translation? One way to achieve the
production of specific gene products (rather than suppressing translation overall) is by
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introducing small interfering RNA (siRNA) into the cell3. The ability to deliver RNA to a
cell is by now well established, witnessed by the mRNA vaccines which, at this writing,
are being administered en masse for the first time to combat the COVID-19 pandemic4,5.
The conceptual methods demonstrated here may be used to quickly assess the affinity of
siRNA constructs, and, perhaps more importantly, semi-synthetic modifications which
may prove to be more effective.
Membrane Studies
Conceivably, any ligand that can be captured in the analytical chamber for
analysis can be measured. A major limitation for this and other systems (e.g., SPR or
ELISA) has been capturing ligands to transmembrane or membrane-bound proteins for
which a soluble fragment is unavailable or even unknown. In this work, we show that:
1) Liposomes produced from natural or artificial membranes can potentially be
easily immobilized in a straightforward manner to the beads used in the KinExA flow cell
for use as capture elements.
2) Liposomes so immobilized will successfully capture ligands of interest,
whether they be target-specific molecules (e.g., antibodies or toxins) or generalized
molecules (e.g., dyes).
3) Kinetic parameters of academic and commercial interest can be determined
using the liposome immobilization process coupled with KinExA analysis.
Note that the first assertion states that natural membranes can “potentially” be
immobilized. Erythrocytes are significantly less complex than other cells, in that they are
essentially devoid of organelles. Purified membranes, or “ghosts,” are entirely composed
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of cytoplasmic membrane, and readily form liposomes under the conditions described in
Chapter Three.
Numerous preliminary experiments were not successful in attaching whole cells
to beads, but led to the concept of forming the membranes into tiny liposomes and
attaching the liposomes to the beads through a cholesterol linker. The much smaller
liposomes would be expected to have more structural integrity than the larger whole cells,
and to be less apt to come off or break up under shear.
Studies presented here promise to extend the use of KinExA analyses to
unpurified and even unknown cell surface reactants, together with determining the
density of the binding sites present on particular membrane systems. The successful
coating of PMMA beads with RBC-derived natural liposomes, and the recovery of antiRBC antibodies by the same in the KinExA procedure, suggest a number of further
studies.
As mentioned above, RBCs are relatively simple cells, devoid of organelles.
Membranes recovered from lysed RBCs are, therefore, entirely and uniformly cell
membranes. Other cell types will pose additional challenges. Numerous protocols exist
for the isolation and purification of cellular and organelle membranes6, and preparation of
liposomes from membranes so isolated should be thoroughly investigated.
Rathanaswami et al.7, used KinExA to conduct affinity measurements of
antibodies to unpurified antigen, by equilibrating the antibodies with whole cells,
capturing the residual free antibody on beads coated with a heterospecific antiimmunoglobulin. Using the same general scheme, residual ligand could be captured by
beads coated with natural liposomes. Would it even be necessary for the resulting
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liposomes to be a homogeneous presentation of cellular membrane? Would it matter if
nuclear, endoplasmic reticulum or mitochondrial membrane were present? The important
parameter is that free ligand from the equilibrium phase of the experiment be captured
and measured.
Isolation and purification of membrane proteins frequently involves solubilization
of the membrane with detergents, assuming that the membrane anchored or
transmembrane protein maintains its native properties when sequestered within the
resulting detergent micelle. This may not be the case. Membrane fractions from lysed
cells may be isolated by ultracentrifugation on a discontinuous sucrose density gradient8.
Efforts to form and characterize liposomes from these fractions may prove fruitful.
All the advantages exhibited by KinExA are anticipated to be maintained with
novel capture elements. KinExA is highly accurate and reproducible9. It avoids matrix
interference in analysis, both at the surface of the capture element10,11 and in the
analytical milieu12. Mobility effects due to mass transport or molecular weight pose no
limitations13,14. As it measures only free ligand in solution, it avoids surfaceimmobilization procedures that may alter binding constants compared to those measured
in true solution phase. The instrument has been used to examine binding partner
interactions from chelated ions15,16 and small molecules17,18 to whole cells7,19–21. The
ability to reveal complex binding stoichiometries, demonstrated in Chapter Two and
elsewhere17,22, may provide valuable insights into fundamental analyses of aptamer–
analyte and surface protein interactions, while its high sensitivity and accuracy suggest
that this technique will be useful for even more bioanalytical applications.
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